Summary

Millipore is a global leader in the life science tools market. Together with our customers, we help to advance the research, development, and production of drugs. Our innovative products and services are used to support life science research, drug discovery, process development, drug manufacturing, and quality assurance. We help customers to improve laboratory productivity and workflows, prioritize potential drugs, optimize manufacturing productivity, and support commercial scale manufacturing.

We manage our business globally and are organized in two operating divisions. Our Bioscience Division provides products and technologies to support life science research and development activities. Our Bioprocess Division provides products and services to support pharmaceutical and biotechnology manufacturing.

The breadth of our product offering and our global scale make us a strategic supplier to the life science industry and provide us with access to many different segments of the market. Our products and services are primarily used by a diverse, global customer base including biotechnology and

pharmaceutical companies, academic institutions and research laboratories. In addition, we derive most of our revenues from consumable products. These attributes allow us to target growth on a number of dimensions and make our business less susceptible to economic downturns, which we experienced in 2009.

Our History

Millipore Corporation was formed as a Massachusetts corporation in 1954. During much of our history, we have developed and sold products based on our proprietary filtration and other separations technologies to a variety of industries. In 2001, we made a strategic decision to focus primarily on the life science markets. Beginning in 2005, we began implementing a strategy that sharpened our focus on the fast growing biopharmaceutical manufacturing and life science research markets. During this time, we have made acquisitions to transform Millipore into a larger and more innovative company. These acquisitions expanded the products and services we offer and complemented our brand, sales force, and customer relationships.

Our Business

OVERVIEW

We compete in the life science tools market and focus on serving the needs of life science researchers and biopharmaceutical manufacturers. We are organized in two operating divisions: Bioscience and Bioprocess. Our Bioscience Division, which contributed approximately 44% of our 2009 revenues, improves laboratory productivity and work flows by providing innovative products and technologies for life science research. Our Bioprocess Division, which contributed approximately 56% of our 2009 revenues, helps pharmaceutical and biotechnology companies develop their manufacturing processes, optimize their manufacturing productivity, and ensure the quality of drugs.

We believe both divisions have attractive business models and share a number of characteristics in common, such as a premium brand, a global presence, a highly qualified sales force, and substantial technical expertise. They also possess a number of characteristics that are unique to the specific markets they serve, which we list in the table on the right. The unique characteristics of our Bioprocess and Bioscience divisions provide us with a balanced and resilient business.

Our business is well-diversified across different life science end-markets, product lines and geographies. We sell thousands of different products, and we are continually developing and/or acquiring new proprietary products and technologies to advance our businesses. Most of our products are consumables that are used, disposed, and replaced, such as reagent kits or filtration cartridges.

These consumable products are less susceptible to fluctuations in capital spending typically associated with hardware and instrumentation products, and therefore provide us with a resilient revenue stream. We derive a small portion of our revenue from hardware products including small benchtop laboratory water systems, large filtration systems, and other detection instruments. We also derive a small portion of our revenue in both divisions from services. Some of the services we provide include outsourced research services for pharmaceutical and biotechnology companies, maintenance services for laboratory instruments, and testing services on biological samples.

We believe there are several key global market drivers that will create increased demand for our products and services. We have developed our strategy to maximize our exposure to these positive drivers. The primary market factors that drive demand for our two operating divisions include:

Growth of biologics

Investments into life science research

Advances in research and scientific innovation

Growth in emerging economies

Drive for higher manufacturing efficiencies and yields

Pharmaceutical outsourcing of services

Need for greater research productivity

Because of the differing applications required by each of our target markets, we believe our business benefits from specialized expertise and market focus. Accordingly, we have aligned our business to better address each of these markets. The following describes more specifically the principal markets in which we compete.

LABORATORY/LIFE SCIENCE RESEARCH MARKETS

Industry Background

As researchers seek to understand complex biological systems and identify and characterize new therapeutic targets, the market demand for tools and services that improve productivity and efficiency in the laboratory has grown.

These researchers are conducting complex and expensive research to help them fundamentally understand the science of biology — what occurs inside the human body. This research is required to feed the pipeline of biologics, cell-based vaccines, and other therapeutic and diagnostic products in development.

Researchers have come under increasing competitive and economic pressure to screen and identify new drugs with more speed and accuracy. In particular, the rapid growth in the development of new biotechnology drugs has brought a heightened focus on protein research, including protein identification and characterization. Additionally, academic researchers are under pressure to increase the speed with which they publish their research in scientific journals in order to compete for public and private funding of their research projects. Laboratory markets have also grown with the increase in concerns about new public health threats.

Our Bioscience Division focuses on four key life science markets: laboratory water, cell biology, protein research, and drug discovery. We target these markets because we believe they are rapidly growing and we can provide competitively superior products, services, and work flow solutions.

Researchers in these specific segments of the market want reduced complexity in their experimental work flows, increased confidence in their scientific outcomes, and ongoing support during their experiments. Our Bioscience strategy is to create products and services that span the entire work flow by simplifying the work flow for researchers, offering consolidated and validated solutions, and providing the necessary support along the way. Due to the complex nature of our four key markets and the diverse yet specialized needs of our customers, we offer products to advance life science research in a wide variety of areas from neuroscience, infectious disease, oncology, and metabolic disorders to stem cells, cell signaling, nuclear function, and chromatin biology.

To address these markets, our Bioscience Division is organized as follows:

Life Science

26% of Company Revenues

We are focused on serving the cell biology, protein research, and drug discovery markets with our life science product offerings. We sell thousands of products into these three markets, including instruments, consumable devices, reagents and services, to help customers better understand diseases and biological functions.

Their work typically involves conducting experiments on biological samples, such as cells, proteins, and nucleic acids.

We also sell drug discovery products and services that help pharmaceutical and biotechnology companies discover, evaluate, and prioritize potential drugs. Historically, we categorized drug discovery sales as a separate product application and reported that drug discovery revenues represented 5 percent of our total revenues in 2008. During 2009, we re-categorized our drug discovery revenues into life science because of the synergy and customer overlap of our multiplex immunoassays with our existing life science product offerings in cell biology and protein research.

CELL BIOLOGY & PROTEIN RESEARCH

Most researchers follow a work flow protocol that requires the use of a broad range of products, including consumable devices, reagents, kits, antibodies, and other molecular biology tools for purifying, preparing, or screening biological samples. We offer product and service solutions designed around the entire protocol, so researchers can work faster, better, and easier than if they did not use our products and services. Many of our life science products span across both the protein research and cell biology markets. These product categories are listed to the right.

Analytical Sample Preparation

The consistency and reproducibility of experimental results requires that samples used by researchers are pure and properly isolated. The varying physical and biochemical characteristics of biological samples make the processes of isolation extremely complex. Research, clinical, and analytical laboratories use many sample preparation steps for a variety of laboratory procedures. Our filtration devices and specialty membranes are designed to accommodate the parameters of a wide variety of experiments.

Antibodies & Reagents

Our customized antibodies serve as biological markers that can be used to produce consistent and repeatable results, saving time, and reducing costs. Research scientists also outsource various services such as the development and production of custom antibodies, which we provide. Life science researchers who study the structure and function of cells and proteins require innovative and high-quality biological reagents to conduct their experiments consistently. A reagent is a substance used to detect, quantify, produce, modify or otherwise manipulate a biological target. Millipore offers a wide range of biological reagents. We also offer a wide variety of kits that improve research productivity and efficiency. Kits enhance research productivity by combining in one box all the disposables, reagents, and protocols needed to reliably and reproducibly conduct a particular experiment.

Within the protein research market, we offer multiplex immunoassay and ELISA kits, protein detection products, and flow cytometry instruments and kits. Researchers use our multiplex immunoassay kits to understand which proteins may be indicative of a disease state, measure how a drug affects protein biomarkers, and determine what side effects a drug creates. We are a leader in developing multiplex kits, reagents, and assays for researchers studying immunology, inflammation, and metabolic diseases (diabetes, obesity, cardiovascular disorders).

We entered the flow cytometry market through our partnership and subsequent acquisition of Guava Technologies. Flow cytometry is a powerful research technique used by scientists to measure changes in protein expression in individual cells. Today, many of these experiments are conducted in centralized, or core, laboratories. Millipore is integrating instrumentation, reagent kits, validated protocols, and technical support to bring the advantages of flow cytometry to the bench tops of cell biologists. As a result, researchers who are growing or monitoring cells can benefit from this analytical platform by conducting cell analysis at the bench rather than running routine assays at a core laboratory.

Within the cell biology market, we offer products for cell culture productivity and specialty cell systems. These products include specialty cell lines, such as stem cell lines that are used to study their role in disease. We also sell a variety of products that are used to prepare, grow, and genetically modify cells.

DRUG DISCOVERY SERVICES

A major challenge for our customers is to find promising drug candidates faster and then ensure that they will not generate unwanted or unexpected side effects in clinical trials or when they are commercially on the market. To improve the efficiency and economy of this research, these customers outsource research work to Millipore rather than conduct the work in-house. We provide services to identify disease targets and better understand how to improve the efficacy of drugs on targeted patient groups and prevent side effects.

Our services offering consists of lead optimization services to help pharmaceutical customers screen small molecule compounds against drug targets of interest, particularly kinases, ion channels and G-Protein Coupling Receptors (“GPCR”), and biopharmaceutical services to help customers better understand the safety and efficacy of biologic drugs and vaccines.

As an increasing number of biologics enter the pipeline, companies are leveraging our expertise to help them evaluate the efficacy of biologics. We help our customers by providing a broad range of services to assist with evaluating and advancing these therapeutics from the drug development pipeline to the market. This offering includes biomarker analytical services, assay transfer/development, validation and sample analysis, pharmacokinetics,

toxicokinetics, immunogenicity, biological potency, and vaccine services.

Laboratory Water

18% of Company Revenues

Most research starts with the use of purified water, which is a universal reagent in scientific experiments. Water purification systems are present in nearly every laboratory. Daily demand for purified water can range from a few liters to several thousand liters. We offer a wide selection of sophisticated benchtop laboratory water instruments that ensure water purity for critical laboratory analysis and clinical testing. These benchtop instruments provide the flexibility to produce the water quality needed for a variety of laboratory needs and applications.

Water quality is a critical variable for researchers to control since contaminated water can adversely affect the scientific outcome of a research project. The level of water purity needed depends on the complexity of the scientific experiment the researcher is conducting. More complicated experiments require extremely high levels of water purity. Millipore offers a range of lab water instruments to meet the diverse water purification needs of our customers. These products remove micro-organisms, dissolved gasses, particulates, and organic and inorganic compounds from water.

Approximately 60 percent of our laboratory water revenues are derived from consumables and service, while approximately 40 percent is derived from lab water instruments.

BIOPHARMACEUTICAL MANUFACTURING MARKETS

Industry Background

Our Bioprocess Division provides products, services, and integrated solutions to help companies manufacture drugs efficiently and ensure drug purity and safety. Our products are primarily used in the production of biologic and synthetic drugs. Manufacturers of these products are under increasing competitive and economic pressure to maintain safety and quality, shorten production times, and improve manufacturing productivity and yields.

Manufacturing of therapeutics generally encompasses small molecule drugs and large molecule drugs. Small molecule therapeutics are primarily chemical compounds that are made through an organic or inorganic chemistry process. These are sometimes referred to as synthetic pharmaceuticals, which are generally manufactured in bulk.

Large molecule therapeutics are primarily protein-based biologics, which are derived from living organisms, generated in a bioreactor or fermentor. They include therapeutic products and vaccines based on recombinant proteins, such as monoclonal antibodies, and represent the fastest growing segment in the drug industry. About half of our Bioprocess business is related to the production of biotechnology drugs.

In many instances, recombinant proteins replace or mimic naturally occurring human proteins and are produced by cells containing modified DNA. One subset of recombinant protein-based drugs, monoclonal antibodies, has been shown to be extremely effective at treating otherwise intractable diseases such as cancer. This efficaciousness has led to a fast growing market for monoclonal antibodies, which are difficult to produce and require a variety of complex technologies and processes to enable their development and production.

Industry sources predict that volumes of monoclonal antibodies and cell-based vaccines will continue to grow substantially over the next five years.

In addition, applications and approvals for biologic drug supplements, which address incremental indications for a previously approved biologic, are also on the rise. In contrast, growth in sales of small molecule pharmaceuticals is expected to be lower because of intense generic competition as the patents expire on the chemical compounds comprising the drugs. Synthetic pharmaceuticals, however, continue to constitute a significant percentage of all marketed therapeutic products and are manufactured in large volumes.

As the demand for marketed biologics and vaccines grows and new products and applications are approved, the market for products that facilitate and accelerate the identification, development, and production of biologics and cell-based vaccines is expanding. Successfully bringing a biologic or a cell-based vaccine to the market is a complex and lengthy process. It begins with extensive laboratory research and discovery; continues with years of development, clinical trials and scale-up of the manufacturing process; and culminates with satisfying regulatory requirements and commencement of commercial production.

The value chain of our Bioprocess customers includes:

Process development and scale up

Upstream bioprocessing (the growth and expression of proteins in bioreactors)

Downstream purification and filtration (the harvesting and refinement of therapeutic proteins)

Monitoring and testing

We believe we offer one of the industry’s broadest product offerings for biopharmaceutical production. Additionally, we believe we are the only company to offer consumable products in both upstream and downstream bioprocessing. Our Bioprocess Division serves the breadth of this development and production process by targeting the three principal applications described below. The development of a customer’s process involves aspects from each of these three product applications.

Upstream Bioprocessing

5% of Company Revenues

Biologic products must be grown in living cells since they cannot be made chemically. We provide products and technologies that improve the ability of cells to efficiently produce proteins that ultimately become therapeutic drugs and vaccines.

The cells are grown in cell cultures held in large bioreactors or fermentation tanks of varying capacity. In order to achieve high protein concentrations, cells in the bioreactor require nutrients and supplements. As the cells grow and metabolize, they secrete into the cell culture medium the therapeutic protein that is then harvested, purified, and further processed.

To facilitate the manufacture of biologic drugs in mammalian cell cultures, we offer high-quality nutrients and supplements for these cultures. Our products include the leading branded fatty acid supplements, recombinant insulin, bovine serum albumin, and other growth factors that improve the ability of cells to produce proteins efficiently. We also offer unique gene expression technology which permits screening and isolation of highly productive cell lines much faster than conventional technologies. This technology enables our customers to more efficiently produce recombinant proteins in mammalian cells by generating higher protein yields. Today, some of our upstream products are derived using materials from animals. Many customers are increasingly demanding products that do not use animal-derived products. We are actively expanding our portfolio of animal-free cell culture supplements through our collaboration with Novozymes and have several animal free supplements currently on the market.

We also launched our first disposable bioreactor from our partnership with Applikon Biotechnology, the Mobius CellReady™ 3L Bioreactor. Mobius CellReady™ can be used by customers during process development and eliminates the cleaning, sterilizing, and assembling required for traditional glass bioreactors. We believe that process development represents an untapped market for the use of disposable technologies. In 2010, we expect to launch additional CellReady products, which will provide researchers with higher capacity bioreactors.

Downstream Bioprocessing

40% of Company Revenues

FILTRATION & CHROMATOGRAPHY

The production of biologics requires the extraction of proteins from the fluids in which these proteins are grown. The process also requires the removal of impurities such as bacteria, viruses, cellular debris, and other contaminants. Accordingly, manufacturing processes for biologics, particularly for monoclonal antibodies and vaccines, are separation-intensive, often requiring numerous filtration and chromatography steps for separation, clarification, concentration, and sterilization.

A complex biologic, such as a monoclonal antibody, requires a significant number of steps to purify the drug, while a typical synthetic drug requires far fewer purification steps.

We offer the broadest range of filtration, purification, and chromatography technologies to clarify, concentrate and purify proteins, and remove viruses or other biological contaminants from biologics, vaccines, synthetic pharmaceuticals, and beverages. Approximately half of our business is related to biologic drug production, with the remaining portion of our business primarily related to synthetic pharmaceutical manufacturing and beverage processing. Many of the same products used in the biotechnology industry are also used to remove contaminants in the production of pharmaceuticals and beverages. We also sell membrane sheets and rolls and bulk chromatography media to original equipment manufacturers of medical devices, environmental testing equipment, or other products for use as a material or component in these products.

DISPOSABLE MANUFACTURING

Until recently, all biologic drugs were primarily produced with stainless steel equipment. This equipment includes large bioreactors, chromatography columns, and other systems used in the large-scale production of biologic drugs. The use of these stainless steel systems requires a significant amount of cleaning and validation costs prior to running a manufacturing campaign.

Our strategic focus has shifted away from selling and manufacturing stainless steel systems to selling and developing disposable manufacturing solutions. Although stainless steel systems are currently the prevalent processing tools, the industry has sought ways to reduce the costs and delays associated with cleaning and sterilizing such equipment in between manufacturing runs. Contamination risks arise if the equipment is not thoroughly decontaminated of all residual materials from prior production runs. Companies have begun to migrate to single use, disposable technologies that eliminate the need for cleaning and sterilization, thus shortening the time between processing runs.

Biopharmaceutical manufacturers are also seeking flexible manufacturing components and solutions that can be configured and validated to meet customized biological manufacturing needs. Many of these companies have benefited from yield improvements in their processes and are seeking to manufacture drugs using smaller scale processes. This has been a positive trend for our disposable manufacturing solutions as these products are better geared to smaller batch manufacturing than stainless steel equipment.

We are a leading innovator in the transition to disposable manufacturing, offering a broad range of integrated disposable manufacturing solutions. In the past few years, we have developed and/or acquired rights to products and technologies that simplify and reduce the time and expense of steps in the downstream and final fill and finish processes of biotechnology and pharmaceutical drug production.

Process Monitoring

11% of Company Revenues

Regulatory agencies such as the U.S. Federal Drug Administration (FDA) require drug manufacturers to ensure the purity and sterility of products before they are released to the public. This requires sampling and testing of therapeutics throughout the manufacturing process. During nearly all phases of drug development and production, companies take multiple steps to ensure their products are produced safely and without contamination. Millipore provides a broad range of products and services that enable sampling and testing of drugs throughout the manufacturing process to ensure the safety and purity of drugs.

Companies that produce beverages (including wine, beer, and bottled juices and water) also benefit from using our process monitoring products to monitor for microbiological contamination from bacteria and yeast.

Our process monitoring products are designed to test for microbiological, viral or other contamination in biologics and synthetic pharmaceuticals as a quality control or assurance step in their manufacture or processing. We are also developing next-generation technologies that are faster and more sensitive so drug manufacturers can identify

contamination earlier in their processes. We currently offer and continue to develop new process monitoring tools capable of significantly reducing the time-to-result from days or weeks to hours. We also offer outsourced testing for biological and viral contamination of biologics.

Our Customers

The majority of our revenues are related to customers engaged in life science research or biopharmaceutical production.

BIOSCIENCE CUSTOMERS

Our Bioscience Division serves hundreds of thousands of customers engaged in life science research. They conduct academic research, drug discovery and laboratory analysis at universities, biotechnology firms, pharmaceutical companies, and other life science research laboratories worldwide. As a result, we have a significant amount of customer diversification within the bioscience research markets.

While the overall bioscience market is very broad, we do not seek to serve all segments of the market. We focus our

offering on specific market segments such as cell biology, protein research, and drug discovery, which have unique needs. Our laboratory water and some sample preparation products are sold into many different types of research, analytical, and clinical laboratories worldwide and serve a more general, diverse customer base.

BIOPROCESS CUSTOMERS

Our Bioprocess Division primarily serves biotechnology and pharmaceutical companies that develop, manufacture, and sell products for the diagnosis, prevention, and treatment of diseases.

These Bioprocess customers are engaged in the development, scale-up, manufacturing, and testing of therapeutic, vaccine, and diagnostic products, as well as a variety of healthcare and other products.

We also sell products to beverage companies to be used in their production process.

Although no single customer accounts for 10 percent or more of our sales, our Bioprocess Division has significantly higher customer concentration than our Bioscience Division, particularly in the biotechnology market.

Our Strategy

Our strategy is to drive long-term growth in our business by:

Capitalizing on opportunities in large, core markets

Targeting fast growing market segments

Delivering innovative products and services to meet customer needs

Executing strategic acquisitions and partnerships

Investing in sales channels and global infrastructure

We are focused on expanding our leadership in attractive, growing, and important core product categories such as laboratory water, sample preparation, antibodies, filtration, and chromatography. We seek to leverage our industry leadership, global footprint, applications expertise, and brand in these markets to deliver deep, innovative solutions that create superior performance and value for our customers.

We are also selectively focusing on the most attractive segments of the life science tools market where we can establish market leadership, generate the highest levels of growth, and drive competitive differentiation. Some of these fast growing markets include disposable manufacturing, virus filtration, benchtop flow cytometry, stem cell research, multiplex immunoassays, and biopharmaceutical services. From a

geographic perspective, we are focusing on expanding our presence in Brazil, Russia, China, India, and Singapore because of the substantial growth of life science research and biopharmaceutical production in these countries. By selectively pursuing high growth markets, we expect that we will be able to grow our revenues and profitability.

Our ability to anticipate customer needs and deliver high-value differentiated products is a critical part of our strategy. We believe our markets are driven by innovation. A central part of our strategy is to develop new products and services that address unmet customer needs in large markets. Our depth of customer relationships and applications expertise allows us to identify, understand, and address these needs. We are also focused on increasing our growth opportunities by executing strategic acquisitions and partnerships. We can enhance our product portfolio and enter new markets by acquiring key technologies and partnering with leading companies in targeted areas. Finally, we are investing in our sales channels and global infrastructure to support future growth. For example, we have opened new, state-of-the-art customer training and scale-up facilities in Singapore and in Billerica, Massachusetts; we have invested in our e-business platform; and we have expanded our sales and marketing capabilities to drive growth in the future.

Selected 2009 Milestones

STRATEGIC TRANSACTIONS

In 2009, we completed four strategic transactions, which we show in the chart on the right:

Acquired Guava Technologies – Q1 2009

Acquired EpiTag™ technology from Epitome Biosystems – Q1 2009

Acquired BioAnaLab Limited – Q3 2009

Purchased remaining 60% ownership of our joint venture in India – Q4 2009

SUSTAINABILITY

We are committed to sustainable growth. In our view, sustainability means being able to operate efficiently and productively while minimizing the impact of our operations and products on the environment. Accordingly, we formally announced in 2008 an ambitious multi-year environmental effort to reduce the environmental impacts of our processes, products and facilities. Central to this initiative is our goal to reduce our global carbon footprint by 20 percent from 2006 to 2011. Our initiative encompasses a wide range of programs focused on dramatically reducing our consumption of non-renewable resources, eliminating waste, and adopting other changes that support long-term environmental sustainability.

A key part of our strategy to meet our carbon reduction goal is the implementation of a comprehensive energy management program that includes a combination of energy efficiency and renewable energy projects. We are also active in numerous organizations with similar goals.

The following are some of the milestones we achieved in 2009 in pursuit of this goal.

Completed a 310 Kilowatt onsite solar system installation at two of our Massachusetts facilities

Completed our first comprehensive annual sustainability report

Named “Corporate Citizen of the Year” by the New England Clean Energy Council

Reduced our carbon emissions 14 percent below our 2006 baseline, mostly since May 2008

Reduced our use of electricity by 4.3 million kilowatt- hours through efficiency programs

Joined the U.S. Environmental Protection Agency’s Green Power Partnership as part of its commitment to use power generated from environmentally preferable renewable resources.

We intend to continue our leadership in corporate environmental responsibility which we believe will benefit both the environment and our business.

NEW PRODUCTS

In 2009, we introduced many new innovative products resulting from our own internal development as well as through collaborations with companies such as Novozymes and Applikon Biotechnology. We believe our business is

driven by innovation and our ability to successfully launch new products through internal development, acquisitions, and collaborations is critical to our future success. We list some of the products that we launched or introduced in the table below:

Competition

The markets for our products and services are intensely competitive and we compete with a variety of public and private companies. Given the breadth of our product and service offerings, our competition comes from a wide array of competitors, ranging from specialized companies with strengths in niche segments of the life science markets to large manufacturers offering a broad portfolio of products, tools, and services. Many of these competitors have significant financial, operational, sales, and marketing resources, and experience in research and development. In some cases, these and other competitors are also our customers, distributors, and suppliers, and in some circumstances we serve these roles for such competitors as well.

We believe that a company’s competitive position in any of our markets is determined by a varying mix of product availability and performance, quality, responsiveness, technical support, price, and breadth of product lines. Our customers are diverse and we believe they place varying degrees of importance on these competitive attributes.

We believe that we differentiate from our competitors by offering more innovative products, better technical support, and higher levels of product quality. Our global presence, the strength of our brand, and our global sales and marketing capabilities also help us to win business over competitors.

Sales, Marketing, and Customer Support

Our direct sales organization is a critical competitive differentiator for us. An important component of our strategy is to leverage our direct sales organization by expanding our product portfolio available for sale and increasing our penetration of our current customer base.

We sell our products to end users worldwide, primarily through our own direct global sales force. Augmenting our direct sales, we also sell our products through our website and, in selected locations and markets, through independent distributors.

We market to our customers through advertising, trade shows, conferences, and other techniques. Our marketing efforts focus on application development for existing products and on new and differentiated products for newly identified and proposed customer needs. We seek to educate customers about the variety of problems that may be addressed by our products as well as to adapt our products and technologies to the problems identified by our customers. Our technical support services are important to our marketing efforts. These services include assisting in defining a customer’s needs, evaluating alternative solutions, selecting or designing a specific system to perform the desired application, training users, and assisting the customer in compliance with relevant government regulations.

Research and Development

We believe that a strong research and product development effort is important to our future growth. We have added important scale and capabilities to our R&D organization over the past three years.

Our research and development activities are intended both to improve on our extensive core technologies and to create new applications and breakthroughs that complement our business. Our core technologies include:

Assay development

Separation and purification membranes

Chromatography media

Customized monoclonal antibodies

Cell culture supplements

Cell lines

Immunodetection

Disposable manufacturing

Sterile sampling

Sample preparation

Some of these technologies are incorporated into devices, cartridges, and modules of different configurations that span many of our markets while others are focused on a specific or customized application.

We conduct most of our own research and development. We have followed a practice of supplementing our internal research and development efforts by acquiring or licensing new technologies from unaffiliated third parties, acquiring distribution rights for new technologies, and undertaking collaborative or sponsored research and development activities with unaffiliated companies and academic or research institutions when we believe it is in our interests to do so. Additionally, we have greatly expanded our product development capabilities through acquisitions to include antibodies, enzymes, labeling and detection reagents, molecular biology kits, multiplexed immunoassays, cell based assays, and drug profiling services.

For example, we purchased the EpiTag™ technology of Epitome Biosystems to expand our presence in the multiplex immunoassay market and to enable our future development of other novel profiling technologies. Our purchase of Guava Technologies provided a platform for benchtop flow cytometry upon which we have developed an enhanced instrument and suite of customized reagents. We also completed 11 technology agreements in 2009. These agreements help us to bring new products to the market by enabling us to combine our device and applications expertise with valuable technologies from third parties.

We continue to work closely with existing partners such as Novozymes, Applikon Biotechnology, and Dow Chemical to bring new products to the markets.

Global Operations

Supply Chain—Manufacturing and Sourcing

We manufacture the majority of our products in our own manufacturing facilities, primarily at those properties described and listed under Item 2 of this Form 10-K, although we have begun to outsource the manufacturing of select products to more cost competitive locations, primarily in China. Our global supply chain initiative, which began in 2004, has resulted in a new manufacturing landscape through the consolidation of our sites, the implementation of new raw material procurement practices by consolidating our supplier base, and streamlining manufacturing processes through improvements using Lean Six Sigma^® methodologies. In September 2008, we announced the second phase of our global supply chain program, which will result in the closure of five additional facilities and reduction of our customer service and distribution costs. We expect to complete this second phase by the end of 2010.

Environmental Health and Safety

We maintain an active environmental, health and safety group charged with ensuring that our facilities and operations are safe and compliant with applicable laws. We promote a culture of safety and environmental responsibility throughout the company. This group also administers our sustainability initiatives described under Selected 2009 Milestones.

Quality Assurance and Regulatory Compliance

To compete effectively in our markets, we maintain a global quality assurance system and program designed to assure compliance with the stringent requirements of regulatory authorities, voluntary quality standards, industry trade associations, and our customers. Using our quality assurance compliance programs, we conduct periodic audits of each of our facilities. The audits, in combination with performance metrics, are designed to ensure

adherence to regulations and our procedures and to assess the effectiveness of our quality system as a whole. The audits are one component of the key performance indicators that we collect, review, and monitor to maintain our program of continuous improvement and compliance with our established systems and programs.

Most of our operating facilities are registered to ISO 9001:2000 quality standards. The ISO 9001:2000 series of standards is a voluntary quality standard recognized throughout the world.

Our Employees

As of December 31, 2009, Millipore employed approximately 6,100 people worldwide, of whom approximately 2,600 were employed in the United States.

Patents, Trademarks and Licenses

We obtain technology licenses to improve our ability to launch new products and to gain the right to re-sell certain products. We have been granted and have licensed rights under a number of patents and have other patent applications pending both in the United States and abroad. While these patents and licenses in the aggregate are viewed as valuable assets, we believe that no individual patent is material to our ongoing operations. We also own a number of trademarks, the most significant being “Millipore.”

Many of our research reagent products are sold under licenses that have varying terms and conditions. We expect to continue to license new technologies from academic and government institutions, as well as biotechnology and pharmaceutical companies. We use licensed technologies to create new products, including high-value kits and services, many of which address bottlenecks in research laboratories. No single license is material to our business.

Government and Industry Regulation

Many of our activities are subject to regulation by governmental authorities within the United States and similar bodies outside of the United States. The regulatory authorities may govern the collection, testing, manufacturing, safety, efficacy, labeling, storage, record keeping, transportation, approval, advertising, and promotion of our products, as well as the training of our employees. Some of our products are subject to import and export regulations specific to the country of import. Certain of our products are considered “medical devices” under the Food, Drug and Cosmetic Act. Accordingly, these products are subject to the law’s general control provisions that include requirements for registration, listing of devices, quality regulations, labeling, and prohibitions against misbranding and adulteration. These products subject us to regulatory inspection and scrutiny. We believe that we are in substantial compliance with all relevant laws and regulations.

Environmental Matters

We are subject to numerous federal, state, and foreign laws and regulations that impose strict requirements for the control and abatement of air, water, and soil pollutants and the manufacturing, storage, handling, and disposal of hazardous substances and waste. We believe we are in substantial compliance with all applicable environmental requirements. We continue to invest in maintaining facilities that enable our compliance with these environmental laws. These environmental related expenditures have not had a material effect on our financial results. Because regulatory standards under environmental laws and regulations have become increasingly stringent, there can be no assurance that future developments will not cause us to incur material environmental liabilities or costs. See the applicable risk factor under Item 1A of this Form 10-K.

Raw Materials

Our products are made from a wide variety of raw materials that are generally available from alternate sources of supply. For certain critical raw materials, we have qualified only a single source. We periodically purchase quantities of some of these critical raw materials in excess of current requirements in anticipation of future manufacturing needs. With sufficient lead time, we believe we would be able to validate alternate suppliers for each of these raw materials. As described in the applicable risk factor under Item 1A of this Form 10-K, several of these critical raw materials are used in a significant portion of our products, and if we were unable to obtain supply of any one of them, our loss of revenues would be material.

Seasonality

In general, we do not believe our business is inherently seasonal.

Backlog

We do not have a material amount of firm commitments that serve as backlog orders.

Geographic and Segment Information

We are a multinational company with approximately 66 percent of our 2009 sales outside the United States and approximately 51 percent of our long-lived assets outside the United States at December 31, 2009. Geographic and segment information, including the identification of operating segments and their aggregation, is discussed in Note 18 to our consolidated financial statements.

Other Information

Millipore’s corporate headquarters are at 290 Concord Road, Billerica, Massachusetts, and our telephone number at that location is 1-978-715-4321.

The U.S. Securities and Exchange Commission (the “SEC”) maintains an internet website at http://www.sec.gov that contains our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements, and all amendments thereto. All reports that we file with the SEC may be read and copied at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, DC 20549. Information about the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330.

Millipore’s internet website address is www.millipore.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and proxy statements, and all amendments thereto, are available free of

charge on our website as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. In addition, our corporate governance guidelines, the charters of each of the committees of our Board of Directors, our code of ethics (consisting of our Corporate Compliance Policy, our Employee Code of Conduct and our Rules of Conduct) and our Director Code of Conduct are available on our website and are available in print to any Millipore shareholder upon request in writing to “General Counsel, Millipore Corporation, 290 Concord Road, Billerica, MA 01821”.

The certifications of Millipore’s Chief Executive Officer and Chief Financial Officer, as required by the rules adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, are filed as exhibits to this Form 10-K. Millipore’s Chief Executive Officer, Martin D. Madaus, provided an annual certification to the New York Stock Exchange dated June 8, 2009, that he was not aware of any violations by the Company of the New York Stock Exchange corporate governance listing standards.

Lack of early success with our pharmaceutical and biotechnology customers can shut us out of future business with those customers.

Many of the products we sell to the pharmaceutical and biotechnology customers are incorporated into our customers’ drug manufacturing processes. In some cases, once a customer chooses a particular product for use in a drug manufacturing process, it is unlikely that the customer will later switch to a competing alternative. In many cases, the regulatory license for the product will specify the separation and cell culture supplement products qualified for use in the process. Obtaining the regulatory approvals needed for a change in the manufacturing process is time consuming, expensive, and uncertain. Accordingly, if we fail to convince a pharmaceutical or biotechnology customer to choose our products early in its manufacturing design phase, we may lose permanently the opportunity to participate in the customer’s production of such product. Because we face vigorous competition in this market from companies with substantial financial and technical resources, we run the risk that our competitors will win significant early business with a customer making it difficult for us to recover that opportunity.

The suspension or termination of production of a customer’s therapeutic product may result in the abrupt suspension or termination of their purchases of our products, resulting in an unexpected reduction in our revenue.

Success in our Bioprocess Division substantially depends on the incorporation of our products into a customer’s manufacturing process. If this “design in” is achieved, we will likely have the opportunity to sell consumable products to the customer during the life cycle of the customer’s product, which could continue for many years. Our planning and growth projections are built in part on the volume assumptions deriving from these customer successes. If a customer stops production of its product, either temporarily or permanently, our sales to the customer for the applicable product will drop or stop.

A customer may suspend or terminate production of a product, either voluntarily or involuntarily, and related sales and distribution for many reasons. These may include adverse regulatory, competitive, legal or economic circumstances. We have had in the past, and expect to have in the future, situations in which a customer suspends its purchases of our products. A suspension or permanent cessation of a process in which we would otherwise anticipate selling a significant volume of consumables will reduce our revenues and negatively impact our earnings.

Disruptions in the supply of raw materials and distributed products from our single source suppliers could result in a significant disruption in sales and profitability.

Our products are made from a wide variety of raw materials that are generally available from alternate sources of supply. However, certain critical raw materials and supplies required for the production of some of our principal products are available only from a single supplier, as are some products that we distribute. Such raw materials and distributed products cannot be obtained from other sources without significant delay or at all. If such suppliers were to limit or terminate production or otherwise fail to supply these materials for any reason, such failures could have a material adverse impact on our product sales and our business.

If our efforts to integrate acquired or licensed businesses or technologies into our business are not successful, our business could be harmed.

As part of our business strategy, we have grown our business through acquisitions of technologies or of companies that offer products, services and technologies that we believe complement our products, technologies, and services. We expect to continue to grow our business through additional acquisitions if appropriate opportunities arise.

Managing these recent acquisitions and any future acquisitions will entail numerous operational, legal, and financial risks, including:

If our consolidated manufacturing operations were disrupted, we may be unable to supply products to our customers and achieve expected revenues.

In an effort to better serve our customers and to attain efficiencies of scale and expertise, we have consolidated the majority of our production facilities into fewer sites. Each of these remaining facilities serves as our primary production facility for specific product lines. This concentration of production, however, exposes us to a greater risk of disruption to our ability to manufacture and supply our products. If operation at any of these facilities were disrupted, we may not be able to deliver products to our customers and achieve expected revenues or earnings. If we were unable to reestablish production in a timely manner, we may lose customers and have difficulty regaining them.

It is uncertain whether the safety measures and contingency plans that we have implemented or may implement will successfully address the risks that may arise if production is disrupted. Also, there can be no assurance that the insurance that we maintain to protect against business interruption loss will be adequate or that such insurance will continue to remain available on acceptable terms, if at all. The extent of the coverage of our insurance could limit our ability to mitigate for lost sales and could result in such losses materially and adversely affecting our operating results.

If we fail to maintain adequate quality standards for our products and services, our business may be adversely affected and our reputation harmed.

Our customers are subject to rigorous quality standards in order to maintain their products and the manufacturing processes and testing methods that generate them. A failure to sustain the specified quality requirements, including the processing and testing functions performed by our products, could result in the loss of the applicable regulatory license. Delays or quality lapses in our customer’s production line could result in substantial economic losses to them and to us. For example, large production lots of biotherapeutics are very delicate and expensive and a failure of a separation membrane could result in the contamination of the entire lot, requiring its destruction. We also perform services that may be considered an extension of our customers’ manufacturing and quality assurance processes, which also require the maintenance of prescribed levels of quality. Although we believe that our continued focus on quality throughout the company adequately addresses these risks, there can be no assurance that we will not experience occasional or systemic quality lapses in our manufacturing and service operations. If we experience significant or prolonged quality problems, our business and reputation may be harmed, which may result in the loss of customers, our inability to participate in future customer product opportunities, and reduced revenues and earnings.

Reduction in our customers’ research and development budgets and government funding may result in reduced sales.

Our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories throughout the world. Their research and development budgets and activities have a large effect on the demand for our products and services. Fluctuations in our customers’ research and development budgets occur due to changes in available resources, mergers of pharmaceutical and biotechnology companies, spending priorities and institutional budgetary policies. Our Bioscience business could be adversely impacted by any significant decrease in life science research and development expenditures by pharmaceutical and biotechnology companies, academic institutions or government and private laboratories. In addition, short term changes in administrative, regulatory or purchasing-related procedures can create uncertainties or other impediments which can contribute to lower sales.

A portion of our Bioscience sales have been to researchers, universities, government laboratories, and private foundations whose funding may be dependent in part upon grants from government agencies such as the U.S. National Institute of Health (“NIH”) and similar domestic and international agencies. NIH funds are subject to reallocation, reduction or discontinuation, which could impact research projects using our products. Government funding of research and development is subject to the political process, which is inherently fluid and unpredictable. Our revenues may be adversely affected if our customers delay purchases as a result of uncertainties surrounding the approval of government or industrial budget proposals. If researchers were not able to obtain, for any extended period, government funding necessary to purchase our products or if there is a decrease in overall research funding, it could reduce our Bioscience sales and damage our business.

We may be unable to establish and to maintain collaborative development and marketing relationships with business partners, which could result in a decline in revenues or slower than anticipated growth rates.

As a part of our business strategy, we have formed, and intend to continue to form, strategic alliances, license agreements and marketing and distribution arrangements with corporate partners relating to the development, commercialization, marketing and distribution of certain of our existing and potential products to increase our revenues and to leverage our product and service offerings. Our success will depend, in part, on our ability to maintain these relationships and to cultivate additional corporate alliances with such companies.

We cannot ensure that our historical collaborative relationships will be commercially successful or yield the desired results, that we will be able to negotiate additional collaborative relationships, that such additional collaborative relationships will be available to us on acceptable terms, or that any such relationships, if established, will be commercially successful. In addition, we cannot ensure that parties with which we have established, or will establish, collaborative relationships will not, either directly or in collaboration with others, pursue alternative technologies or develop alternative products in addition to, or instead of, our products. Such parties may also be acquired by our competitors to terminate our relationship. They may also experience financial or other difficulties that lessen their value to us and to our customers. Our results of operations and opportunities for growth may be adversely affected by our failure to establish and maintain successful collaborative relationships.

Demand for our Bioprocess products and services are subject to the commercial success of our customers’ products and our customers’ purchasing patterns, which may vary for reasons outside our control.

Even if we are successful in securing participation for our products in a customer’s manufacturing process, sales of many of our Bioprocess products and services remain dependent on the timing and volume of the customer’s production or purchasing patterns, over which we have no control. The customer’s demand for our products will depend on the regulatory approval and commercial success of the supported product, as well as the customer’s manufacturing schedules and related purchasing power. The regulatory process is complex, lengthy and expensive and can often take years to complete, if at all. Commercial success of a customer’s product, which would drive demand in production and commensurate demand for our products and services, is dependent on many factors, some of which can change rapidly, despite early positive indications. Any delay or cancellation by a customer of volume manufacturing may harm our revenues and earnings.

If we experience a significant disruption in our information technology systems or if we fail to implement new systems and software successfully, our business could be adversely affected.

We rely on one centralized information system throughout our company to keep financial records, process orders, manage inventory, process shipments to customers, and operate other critical functions. If we were to experience a prolonged system disruption in the information technology systems that involve our interactions with customers and suppliers, it could result in the loss of sales and customers, which could adversely affect our business. In addition, in order to maximize our information technology efficiency, we have physically consolidated our primary corporate data and computer operations into two geographically proximate facilities. This concentration, however, exposes us to a greater risk of disruption to our internal information

technology systems. If operations at either or both of these centers were disrupted, it would likely cause a material disruption in our business.

Technology innovations in the markets that we serve may create alternatives to our products and result in reduced sales.

Our customers constantly attempt to reduce their manufacturing costs and to improve product quality. Technology innovations to which our current and potential customers would have access could reduce or eliminate their need for our membrane or chromatography products. For example, if a new membrane or chromatography technology of one of our competitors is accepted by the pharmaceutical or biotechnology industry as a market standard, sales of our membrane or chromatography products would be negatively impacted. In addition, a disruptive technology that reduces or eliminates the use of our core technologies would negatively impact the sale of our products. As an example, animal–free serum products are generally favored over bovine serum. We may be unable to respond on a timely basis to the changing needs of our customer base and the new technologies we design for our customers may prove to be ineffective. Our failure to develop and to introduce or to enhance products able to compete with such new technologies in a timely manner could have a material adverse effect on our business, results of operations, and financial condition. We may be unable to respond on a timely basis to the changing needs of our customer base and the new technologies we design for our customers may prove to be ineffective.

We may be unable to realize our growth strategy if we cannot identify suitable acquisition opportunities in the future.

As part of our business strategy, we expect to continue to grow our business through acquisitions of technologies or companies. We may not identify or complete complementary acquisitions in a timely manner, on a cost-effective basis, or at all.

In addition, we compete with other companies, including large, well funded competitors, to acquire suitable targets, and may not be able to acquire certain targets that we seek. There can be no assurance that we will be able to execute this component of our growth strategy, which may harm our business and hinder our future growth.

To achieve desired growth rates as we become larger, we may seek larger or public companies as potential acquisition candidates. The acquisition of a public company may involve additional risks, including the potential for lack of recourse against public shareholders for undisclosed material liabilities of the acquired business.

Our continued growth is dependent on our development and successful commercialization of new products.

Our future success will depend in part on timely development and introduction of new products that address changing market requirements. We believe that successful new product introductions provide a significant competitive advantage because customers make an investment of time in selecting and learning to use a new product. Customers are reluctant to switch to a competing product after making their initial selection. To the extent that we fail to introduce new and innovative products, we may lose market share to our competitors, which will be difficult or impossible to regain. An inability, for technological or other reasons, to successfully develop and introduce new products could reduce our growth rate or otherwise damage our business. In the past, we have experienced, and are likely to experience in the future, delays in the development and introduction of products. We cannot assure that we will keep pace with the rapid rate of change in life science research, or that our new products will adequately meet the requirements of the marketplace or achieve market acceptance.

If we fail to attract, hire, develop and retain qualified personnel, we may not be able to design, manufacture, market or sell our products or successfully grow our business.

As part of our global supply chain initiative to improve customer service and to amplify our product expertise, we have concentrated our facilities in fewer geographical areas in which there is high demand for qualified staff. Competition for individuals with skills including sales, marketing, research, product development, engineering and others is strong and we may not be able to secure the personnel we need. The loss of the services of any key personnel, or our inability to hire new personnel with the requisite skills, could restrict our ability to develop new products and services or enhance existing products and services in a timely manner, sell products to our customers, or manage our business effectively.

Our level of indebtedness may harm our business and prevent our achievement of anticipated growth.

As of December 31, 2009, our total long term debt was $890.2 million. Our level of indebtedness could have important consequences because:

Our operations may not generate sufficient cash to enable us to service our debt. If we fail to make a payment on any of our debt obligations or comply with financial covenants in our debt agreements, we could be in default on such debts, and this default could cause us to be in default on our other outstanding indebtedness.

In each case of default, we may be required to repay all of our outstanding indebtedness or renegotiate the terms of our indebtedness on unfavorable terms.

Sales of several of our products are dependent on a small number of customers, the loss of which may harm our business and result in a reduction in revenues and earnings.

No single customer represents more than 10 percent of our annual sales. However, sales of some of our products are dependent on a limited number of customers, who account for a significant portion of such sales. Continuing consolidation in the biopharmaceutical industry will likely concentrate our customer base further. Some of these products are in areas in which we plan to grow substantially. The loss of such key customers for such products, or a significant reduction in sales to those customers, could significantly reduce our revenues in these products and adversely affect our future growth in such markets.

We may become involved in disputes regarding our patents and other intellectual property rights, which could result in prohibition on the use of certain technology in current or planned products, exposure of the business to significant liability and diversion of management’s focus.

We and our major competitors spend substantial time and resources developing and patenting new and improved products and technologies. Many of our products are based on complex, rapidly developing technologies. Although we try to identify all relevant third party patents and intellectual property rights, these products could be developed by the business without knowledge of published or unpublished patent applications that cover or use some aspect of these technologies. We also license products and technologies developed by other biotechnology companies or academic research laboratories for further resale. We have been and may in the future be sued by third parties alleging that we are infringing their intellectual property rights. These lawsuits are expensive, take significant time, and divert management’s focus from other business concerns.

If we are found to be infringing the intellectual property of others, we could be required to stop the infringing activity, or we may be required to design around or license the intellectual property in question. If we are unable to obtain a required license on acceptable terms, or are unable to design around any third party patent, we may be unable to sell some of our products and services, which could result in reduced revenue. In addition, if we do not prevail, a court may find damages or award other remedies in favor of the opposing party in any of these suits, which may adversely affect our earnings.

Concerns about products that are derived from animal materials, such as bovine serum, will further reduce the demand for our animal-based cell culture products.

The demand for several of our cell culture products will continue to decline due to concerns about the use of animal-based materials in the process by which they are manufactured. The concern arises from the risk that animal contaminants might be present in the raw materials used in the production process and that such contaminants might be introduced into a therapeutic substance manufactured by one of our customers. For example, the regulatory authorities of certain countries, including Japan, have refused to approve pharmaceuticals that are manufactured using a product that was derived from bovine serum or that was manufactured by a process that uses bovine material. The regulatory authorities of other countries could adopt similar restrictions.

Our operations must comply with environmental statutes and regulations, and any failure to comply could result in extensive costs which would harm our business.

The manufacture of some of our products involves the use, transportation, storage and disposal of hazardous, radioactive or toxic materials and is subject to various environmental protection and occupational health and safety laws and regulations in the countries in which we operate.

This has exposed us in the past, and could expose us in the future, to risks of accidental contamination and events of non-compliance with environmental laws. Any such occurrences could result in regulatory enforcement or personal injury and property damage claims or could lead to a shutdown of some of our operations, which could have an adverse effect on our business and results of operations. We currently incur costs to comply with environmental laws and regulations and these costs may become more significant.

The environmental laws of many jurisdictions impose actual and potential obligations on us to remediate contaminated sites. These obligations may relate to sites:

These environmental remediation obligations could reduce our operating results. In particular, our accruals for these obligations may be insufficient if the assumptions underlying the accruals prove incorrect or if we are held responsible for additional, currently undiscovered contamination.

A substantial fine or penalty, the payment of significant environmental remediation costs or the loss of a permit or other authorization to operate or engage in our ordinary course of business could result in material, unanticipated expenses and the possible inability to satisfy customer demand.

Our sales may be negatively affected by the implementation of second source programs by our customers.

For many customers, we are the single source supplier for one or more critical components used in their production lines. We are aware of customers that have begun to implement second sourcing programs to reduce the potential risk of disruptions to their production due to a supply bottleneck. These can include diversifying purchases of one component among vendors or spreading the sources of components of a process, such as purification, among different suppliers. If, as a result of these second sourcing

programs, existing customers were to choose another company to supply components that we currently supply, or if we lose future business opportunities for which we would otherwise be qualified, our future revenues may be harmed.

Our use of third party manufacturers exposes us to increased risks that may affect our ability to supply our customers.

As part of our efforts to consolidate our manufacturing operations and reduce cost, we have increased the outsourcing of certain manufacturing operations. In addition, we often source products resulting from collaborative development relationships from such development partners. Our increased dependence on third party contract manufacturers exposes us to increased risks associated with delivery schedules, manufacturing capability, quality control, quality assurance, and costs. If any of our third party manufacturers experiences delays, disruptions, capacity constraints or quality control problems in its manufacturing operations or becomes insolvent, then product shipments to our customers could be delayed, which would decrease our revenues and harm our competitive position and reputation.

Because we compete directly with one of our significant distributors, our results of operations could be adversely affected if such party discontinues or materially changes the terms of the agreement.

One of our competitors also serves as a significant distributor. If this distributor discontinued selling our products or materially changed the terms, our sales and earnings could be adversely affected in the short term.

Violation of government regulations or voluntary quality programs could result in loss of sales and customers and additional expense to attain compliance.

Several of our facilities are subject to extensive regulation by the FDA and similar governmental bodies in other countries.

These facilities are subject to periodic inspection by the FDA and other similar governmental bodies to ensure their compliance with applicable laws and regulations. New facilities, products and operating procedures also may require approval by the FDA and/or similar governmental bodies in other countries. Failure to comply with these laws and regulations could lead to sanctions by the governmental bodies, such as written observations of deficiencies made following inspections, warning letters, product recalls, fines, product seizures and consent decrees, which would be made available to the public. Such actions and publicity could affect our ability to sell products and to provide our services.

Several of our operations are also subject to U.S. Department of Agriculture regulations and various foreign regulations for the sourcing, manufacturing and distribution of animal based proteins. Our failure to comply with these requirements could negatively impact our business and potentially cause the loss of customers and sales. ISO 9001:2000 quality standards are an internationally recognized set of voluntary quality standards that require compliance with a variety of quality requirements somewhat similar to the requirements of the FDA’s Quality System Regulations, which were formerly known as Good Manufacturing Practices or GMP. Some of our facilities are registered under the ISO standards. Failure to comply with this voluntary standard can lead to observations of non-compliance or even suspension of ISO certification by the certifying unit. Loss of ISO certification could cause some customers to purchase products from other suppliers.

We are subject to economic, governmental, political, legal and other risks associated with our significant international sales and operations, which could adversely affect our business.

We conduct operations throughout the world through a variety of subsidiaries and distributors. Sales outside the

United States were approximately 66 percent and 67 percent of total sales in 2009 and 2008, respectively. A significant portion of our 2009 revenues is generated in Europe and Asia/Pacific, approximately 40 percent and 20 percent, respectively. We anticipate that revenue from

international operations will continue to represent a significant portion of our revenues. In addition, two of our primary manufacturing facilities, Molsheim, France and Cork, Ireland, and many of our employees and suppliers, are located outside the United States. Our sales and earnings could be adversely affected from our international operations, including:

Foreign exchange fluctuations may adversely affect our reported earnings, the value of our assets and the cash outflow for our debt repayment.

We prepare our consolidated financial statements in U.S. dollars, but a significant portion of our earnings and expenditures are in other currencies. In 2009, we derived about 66 percent of our revenues from customers outside the United States. Our sales made in countries other than the United States are typically made in the local currencies of those countries. As a result, fluctuations in exchange rates have caused and will continue to cause foreign currency gains and losses. Fluctuations in exchange rates between the U.S. dollar and other currencies may also affect the book value of our assets outside the United States. We have a significant amount of our debt denominated in Euro. A significant appreciation of the Euro with respect to the U.S. dollar could expose us to additional interest and principle payments.

Due to the number of currencies involved, the variability of currency exposures and the potential volatility of currency exchange rates, we cannot predict the effects of exchange rate fluctuations on future operating results. We seek to mitigate our currency exposure by coordinating our worldwide supply sourcing, actively managing cross-border currency flows, and engaging in foreign exchange hedging transactions. Despite these steps, there can be no assurance that our foreign currency management strategy will adequately protect our operating results from the effects of future exchange rate fluctuations.

Our revenues may fluctuate, and this fluctuation could cause financial results to be below expectations.

Fluctuations in our operating results from period to period may occur for a number of reasons. In planning our operating expenses for the foreseeable future, we assume that revenues will continue to grow. Generally operating expenses cannot be adjusted quickly in the short term because we have significant fixed costs. If our revenues decline or do not grow as anticipated, we may not be able to reduce our operating expenses accordingly. Failure to achieve anticipated levels of revenue could therefore significantly harm our operating results for a particular period.

A revenue shortfall could arise from any number of factors, some of which we cannot control. For example, factors that may cause our results to vary by period include:

the volume and timing of orders from customers for our products and services

the level and timing of our customers’ research and commercialization efforts

changes in the mix of our products and services

the number, timing, and significance of new products and services introduced by our customers

our ability to develop, market and introduce new and enhanced products and services on a timely basis

changes in the cost, quality and availability of materials and components required to manufacture or use our products

the timing and costs of any acquisitions of businesses or technologies

the introduction of new products by us or our competitors

exchange rate fluctuations

general economic conditions.

Increased exposure to product liability claims could adversely affect our earnings.

Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products offered by our customers. Currently these risks are primarily borne by our customers. As our products and services are further integrated into our customers’ production processes, we may become increasingly exposed to product liability and other claims in the event that the use of our products or services is alleged to have resulted in adverse effects. There can be no assurance that a future product liability claim or series of claims brought against us would not have an adverse effect on our business or the results of operations. Our business may be materially and adversely affected by a successful product liability claim or claims in excess of any insurance coverage that we may have. In addition, product liability claims, regardless of their merits, could be costly and divert management’s attention, and adversely affect our reputation and the demand for our products.

The stated value of long-lived and intangible assets, including goodwill, may become impaired and result in an impairment charge.

As of December 31, 2009, we had $1,951.0 million of long-lived and intangible assets, including goodwill. We continue to invest in the construction and upgrading of our manufacturing and research facilities, which may have the effect of increasing the recorded value of our long-lived assets. If we are successful in acquiring additional complementary businesses and technologies, a substantial portion of the value of these may be recorded as goodwill, an intangible asset.

The carrying amounts of long-lived and intangible assets may be affected whenever events or changes in circumstances indicate that the carrying amount of any asset may not be recoverable. Such events or changes might include, but are not limited to, the following: significant underperformance relative to expected historical or projected future operating results, significant negative industry or economic trends, or significant changes or developments in strategy or operations that negatively affect the utilization of our long-lived assets. Adverse events or changes in circumstances may affect the estimated undiscounted future operating cash flows expected to be derived from long-lived and intangible assets. If at any time we determine that an impairment has occurred, we will be required to recognize an impairment charge, resulting in a reduction in earnings in the quarter such impairment is identified and a corresponding reduction to our assets. The potential recognition of impairment in the carrying value, if any, could have a material and adverse effect on our results of operations.

We may require substantial additional capital to pursue strategic acquisitions or alliances, which capital we may not be able to obtain on commercially reasonable terms, if at all.

We anticipate that our currently planned capital requirements will be satisfied by the future operating cash flows, current cash balances, borrowings under our revolver, or

other existing financing sources. To the extent that we desire to pursue a strategic acquisition or alliance requiring substantial cash expenditures for which our existing resources and credit facilities are insufficient, we may need to raise funds through public or private debt or equity financings. There is no assurance that such additional funds will be available or, if available, that we can obtain such funds on terms acceptable to us. If adequate funds are not available, we may have to forgo desired acquisitions or alliances.

Future issuances of common stock may depress the trading price of our common stock and our convertible notes.

Any issuance of equity securities, including the issuance of shares upon conversion of our convertible notes, could dilute the interests of our existing stockholders, including holders who have received shares upon conversion of their notes, and could substantially decrease the trading price of our common stock and our convertible notes. We may issue equity securities in the future for a number of reasons, including to finance our operations and business strategy (including in connection with acquisitions, strategic collaborations or other transactions), to adjust our ratio of debt to equity, to satisfy our obligations upon the exercise of outstanding warrants or options or for other reasons.

Dr. Madaus joined Millipore Corporation as our President and Chief Executive Officer, and as a Director, on January 1, 2005, and was appointed Chairman of the Board effective March 1, 2005. From 2000 until December 2004, Dr. Madaus served as President and Chief Executive Officer of Roche Diagnostics Corporation, heading the North American diagnostics business of Hoffmann-La Roche, a leading pharmaceutical and diagnostics company. Prior to that, Dr. Madaus held various management positions from 1989 to 1999 with Hoffmann-La Roche and with Boehringer Mannheim (prior to its 1998 acquisition by Hoffmann-La Roche). Dr. Madaus also serves as a board member of Mettler-Toledo International, Inc. and the Massachusetts High Technology Council.

Mr. Bonnevier joined Millipore Corporation as Vice President of Global Human Resources in January 2006. From 2004 to 2005, Mr. Bonnevier served as Vice President of Human Resources for Hillenbrand Industries, Inc., a company that owned and operated businesses that provide products and services for the health care and funeral services industries. From 2000 to 2004, he was Vice President of Human Resources for Shipley Company, now the Electronic Materials Division of the Rohm and Haas Company

(a wholly owned subsidiary of The Dow Chemical Company), a leading producer of specialty materials used in a wide variety of applications, including electronic materials, paints and personal care products. From 1989 through 2000, Mr. Bonnevier held various senior management roles at Rohm and Haas, including Director of International Human Resources and Business Human Resources Manager.

Mr. DiVincenzo was elected Vice President of Millipore Corporation in January 2009 and serves as President of our Bioscience Division. From July 2006 through December 2008, he served as Vice President, Worldwide Sales and Service for our Bioscience Division, and from January 2005 through June 2006, as the Bioscience Division’s Vice President of Marketing and R&D. From January 2001 through January 2005, Mr. DiVincenzo served as the Vice President of Marketing and R&D for our Lab Water Division, which combined with other businesses to become our Bioscience Division. Prior to such roles, Mr. DiVincenzo held a wide variety of positions since joining us in 1994, including several senior marketing and product management positions within our Lab Water business.

Dr. Harris joined Millipore Corporation as our Chief Scientific Officer following our acquisition of Serologicals in July 2006. From 2004 to 2006, Dr. Harris served as Vice President, Global Research & Development and business development and Chief Scientific Officer at Serologicals. From 2002 to 2003, Dr. Harris served as Executive Vice President, Research & Development for Vitra Biosciences, Inc., a developer of cell-based drug screening array systems for drug discovery. From 2001 to 2003, Dr. Harris held senior Research & Development and business positions at ACLARA Biosciences, Inc., a developer of novel technologies in the areas of microfluidics and gene and protein analysis. For approximately twenty years prior to joining ACLARA, Dr. Harris held positions of increasing responsibility at Amersham Pharmacia Biotech, Inc. and its affiliates, most recently as Vice President of Research and Development for North America and global genomics Research and Development from 1997 to 2001. Amersham (acquired by General Electric Corporation in 2004) is a manufacturer of pharmaceutical products for the diagnosis and treatment of disease and of technologies for biotechnology research and drug discovery.

Mr. Ide joined Millipore Corporation in 2005 as Vice President, Millipore International, with responsibility for market development opportunities in Japan, Asia, India, South America, Eastern Europe, the Middle East, and Africa. Prior to joining Millipore, Mr. Ide was employed by Bausch & Lomb Incorporated, a world leader in the development, manufacture and marketing of eye health products, from 1988 to 2005. He served Bausch & Lomb in positions of increasing responsibility, most recently as corporate Vice President and President of Japan Operations from 1999 to 2005.

Mr. Kershaw was elected Vice President, Worldwide Manufacturing Operations, of Millipore Corporation effective February 2004 and, in August 2005, was appointed head of our newly created Global Supply Chain organization, a combination of the Company’s worldwide manufacturing, distribution, and customer service functions. In December 2008, he was appointed head of our newly created Global Operations organization, a combina-

tion of the Company’s global supply chain and corporate quality functions. Prior to joining Millipore, Mr. Kershaw served Hologic, Inc., a manufacturer of medical imaging systems, as Corporate Vice President, Manufacturing Operations (2003-2004) and Vice President and General Manager, LORAD Division (2001-2003). Prior to that, Mr. Kershaw served as President (1998-2001) and Vice President and General Manager (1996-1998) of the Medical Device Division of Bespak plc, a manufacturer of plastic injection molded components and finished medical devices.

Mr. Mangeolle was elected Vice President of Millipore Corporation and President of the Bioprocess Division in October 2005. From 2002 to 2005, he served as Vice President of the Division’s Worldwide Field Operations. From 2001 to 2002, Mr. Mangeolle was Vice President of Operations of Mykrolis Corporation, a spin-off of Millipore’s former Microelectronics Division. Prior to 2001, Mr. Mangeolle held a number of senior management positions in Millipore’s Microelectronics and Laboratory Water Divisions, as well as Millipore’s Asian Operations. Mr. Mangeolle joined Millipore SA, our wholly-owned subsidiary in France, as a sales applications specialist in 1984.

Mr. Rudin was elected Vice President and General Counsel of Millipore Corporation in December 1996 and as Clerk (that office is now known as Secretary) of Millipore in 1999. Prior to joining Millipore, Mr. Rudin served Ciba Corning Diagnostics Corp. as Senior Vice President and General Counsel (1993-1996) and as Vice President and General Counsel (1988-1993).

Mr. Wagner was elected Vice President and Chief Financial Officer of Millipore Corporation effective in August 2007. Mr. Wagner joined Millipore Corporation in December 2002 as Director of Strategic Planning and Business Development and was elected Vice President, Strategic Planning and Business Development (now Strategy and Corporate Development), in March 2003, serving in this role until his election as Chief Financial Officer. Prior to joining Millipore, Mr. Wagner served as a Manager (2001-2002) and Consultant (1998-2001) at Bain & Company.

Millipore’s Common Stock, $1.00 par value, is listed on the New York Stock Exchange and is traded under the symbol “MIL.” The following table sets forth, for the indicated fiscal periods, (i) the high and low sales prices of Millipore’s Common Stock (as reported on the New York Stock Exchange Composite Tape). On February 1, 2010,

there were approximately 32,274 registered and beneficial shareholders of record.

We did not declare any cash dividends during 2009 or 2008. We do not currently have plans to make future cash dividend declarations or payments.

The following selected consolidated financial data are derived from our Consolidated Financial Statements and notes thereto and should be read in connection with and

are qualified in their entirety by our Consolidated Financial Statements and notes thereto and other financial information included elsewhere in this Form 10-K report.

Basis of Presentation

The following Management’s Discussion and Analysis (“MD&A”) will help you understand the financial condition and results of operations of Millipore Corporation. The MD&A is a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes to the consolidated financial statements. We will also be disclosing certain non-GAAP information in the MD&A. A reconciliation of our GAAP financial measures to our non-GAAP financial measures and information about the use of non-GAAP measures begins on page 62 under the heading “Use of Non-GAAP Financial Measures.”

Effective January 1, 2009, we adopted two new accounting standards: (1) for noncontrolling interests and (2) for convertible debt that may be settled in cash upon conversion. These standards required retrospective adjustments to prior period financial statements to conform to current accounting treatment.

General Overview

Millipore is a global leader in the life science tools market. Together with our customers, we help to advance the research, development, and production of drugs. Our innovative products and services are used to support life science research, drug discovery, process development, drug manufacturing, and quality assurance. We help customers to improve laboratory productivity and work flows, prioritize potential drugs, optimize manufacturing productivity, and support commercial scale manufacturing.

We manage our business globally and are organized in two operating divisions. Our Bioscience Division provides products and technologies to support life science research and development activities. Our Bioprocess Division provides products and services to support pharmaceutical and biotechnology manufacturing.

The breadth of our product offering and our global scale make us a strategic supplier to the life science industry and provide us with access to many different segments of the market. Our products and services are primarily used by a diverse, global customer base including biotechnology and pharmaceutical companies, academic institutions, and research laboratories. In addition, we derive most of our revenues from consumable products. These attributes allow us to target growth on a number of dimensions and make our business less susceptible to economic downturns, which we experienced in 2009.

BUSINESS DRIVERS

Bioscience Division

The primary business driver of our Bioscience Division is the research activities of pharmaceutical and biotechnology companies, academic institutions, governments, and other organizations. Demand for our products increases with the amount of research being conducted worldwide. Key market trends affecting the business include the investments in life science laboratories, particularly in Asia, growth in protein research and cell biology, and higher demand for products that improve research work flows.

For example, pressure on pharmaceutical and biotechnology companies to identify new drug candidates has increased demand for our products that help to improve research productivity. Pre-validated, optimized products, especially those combined in kits, increase efficiency and save researchers time. As a result, we have expanded the number of kits we offer to improve research protocols.

Other business drivers of the Bioscience Division include:

Academic and government spending on life science research

Increase in outsourced drug discovery research activities by pharmaceutical and biotechnology companies

New products and customer work flow solutions. For example, work flow solutions that include devices, consumable products, and technical service and expertise

The emergence of the Internet as a key sales channel

An ability to license, commercialize, and acquire technologies

The global economic recession and the continued pharmaceutical industry consolidation reduced our Bioscience Division revenue growth in 2009.

Bioprocess Division

The business drivers of our Bioprocess Division include the demand for, and the corresponding production of, commercial therapeutics such as biologic drugs and vaccines. Over the past decade, several biologics have been approved as therapeutics, including monoclonal antibodies, cell culture-based vaccines, and other recombinant protein-based therapeutics. As pharmaceutical companies shift more of their drug pipeline from synthetic-based drugs to biologic drugs, our business will grow if a greater number of these molecules are commercially approved and if we win production process steps for these biologics.

Monoclonal antibodies are among the fastest growing classes of biologic drugs because of their ability to treat diseases for which there are few therapies. They are separation-intensive, complex to produce, and require significant use of our Bioprocess products. The growth in biologics also creates increased demand for our consumable products.

Our expertise in purifying monoclonal antibodies positions us strategically to gain customer access and increase our applications knowledge. These intimate customer relationships help us identify new technologies and customer needs. They also help our customers optimize their productivity. Therefore, we typically see our revenues increase as a molecule moves from early to late stage clinical development and ultimately receives approval. We generate the highest level of revenues during Phase III clinical trials and during commercial production.

Other business drivers of the Bioprocess Division include:

Commercialization of innovative products that increase production speed and productivity and reduce risk. For example, new biologic drug manufacturing platforms that employ disposable manufacturing solutions

Biopharmaceutical manufacturing capacity expansion, particularly in growth markets in Asia

Increasing customer manufacturing quality standards resulting in the need for more sophisticated process monitoring and quality control

Growth in global demand for novel, seasonal, and pandemic flu vaccines

Market acceptance of cell culture-based vaccines, which require more purification technologies

OUR STRATEGY

Our strategy is to drive long-term growth in our business by:

Capitalizing on opportunities in large, core markets

Targeting fast growing market segments

Delivering innovative products and services to meet customer needs

Executing strategic acquisitions and partnerships

Investing in sales channels and global infrastructure

We are focused on expanding our leadership in attractive, growing, and important core product categories such as laboratory water, sample preparation, antibodies, filtration, and chromatography. We seek to leverage our industry leadership, global footprint, applications expertise, and brand in these areas to deliver deep, innovative solutions that create superior performance and value for our

customers.

We are also selectively focusing on attractive segments of the life science tools market where we can establish market leadership, generate higher levels of growth, and drive competitive differentiation. Some of these fast growing markets include disposable manufacturing, virus filtration, benchtop flow cytometry, stem cell research, multiplex immunoassays, and biopharmaceutical services. From a geographic perspective, we are focusing on expanding our presence in Brazil, Russia, China, India, and Singapore because of the substantial growth of life science research and biopharmaceutical production in these countries. By selectively pursuing high growth markets, we expect that we will be able to grow our revenues and profitability.

Our ability to anticipate customer needs and deliver high-value differentiated products is a critical part of our strategy. We believe our markets are driven by innovation.

A central part of our strategy is to develop new products and services that address unmet customer needs in large markets. Our depth of customer relationships and applications expertise allows us to identify, understand, and address these needs. We are also focused on increasing our growth opportunities by executing strategic acquisitions and partnerships. We can enhance our product portfolio and enter new markets by acquiring key technologies and partnering with leading companies in targeted areas. Finally, we are investing in our sales channels and global infrastructure to support future growth. For example, we have opened new, state-of-the-art customer training and scale-up facilities in Singapore and in Billerica, Massachusetts; we have invested in our e-business platform; and we have expanded our sales and marketing capabilities to drive growth in the future.

2009 HIGHLIGHTS

Consolidated revenues of $1,654.4 million for 2009 increased $52.3 million, or 3 percent, compared to 2008. Adjusting for a 3 percentage point adverse effect from foreign currency translation and a 1 percentage point favorable effect from the Guava acquisition, our consolidated revenues for 2009 grew 5 percent.

Our year-over-year revenue growth during the current economic environment reflects the resiliency of our business model. Approximately 90 percent of our revenues are derived from consumable products and services, which are less affected by the contraction of our customers’ capital spending. Our business is well diversified across end- markets, product lines, and geographies. This diversity provides us important balance and flexibility in managing our business, especially during these challenging economic times.

In 2009, Bioprocess currency adjusted revenues grew 8 percent because of increased spending levels by our large biotechnology customers, sales of products used in vaccine production, new product sales, and increased demand in Asian markets. Bioscience currency adjusted revenues grew 3 percent, which was driven by academic research spending and sales of acquired and new products. The effect of the global economic recession that led to lower demand for our laboratory instrumentation products and weak spending by our large pharmaceutical customers partly offset this revenue growth.

Operating profit increased to $268.6 million in 2009 from $233.5 million in 2008. Higher revenues, favorable impact from changes in foreign currency, and operational efficiencies were the primary drivers of the increase. This profit expansion enabled us to increase our investment in research and development in accordance with our innovation strategy and absorb the effects of an unfavorable product mix which negatively impacted gross margin and higher incentive compensation costs. Our operating profit margin increased to 16.2 percent in 2009 from 14.6 percent in 2008.

Diluted GAAP and non-GAAP earnings per share (“EPS”) were $3.15 and $4.00, respectively, in 2009 and increased by $0.68 and $0.41, respectively, compared to 2008. (Please see our non-GAAP reconciliation which begins on page 62.) Higher operating profit, the gain resulting from our Guava business acquisition, and lower interest expense contributed to higher GAAP EPS. A higher tax rate attributable to pre-tax income mix shift to higher tax rate jurisdictions offset the increase. Excluding the gain resulting from our Guava business acquisition, non-GAAP and GAAP growth drivers were similar for the year.

Free cash flow is an important operating metric that we define as net cash provided by operating activities less additions to property, plant and equipment. We generated $298.1 million of free cash flow in 2009, a 54 percent increase over 2008. This growth was attributable to our increased profitability and better working capital management as a result of implementing our working capital initiative. We made net repayments of $173.3 million on our

debt during the year. As of December 31, 2009, we had no borrowings outstanding under our primary revolving credit facility. This cash flow generation enabled us to fund three strategic acquisitions, to purchase the remaining interest of our joint venture in India, and to fund our innovation strategy.

In 2004, we announced the first phase of our global supply chain initiatives to consolidate manufacturing operations and reduce our fixed costs. In 2008, we announced the

second phase of this program, aimed at further reducing our manufacturing and distribution costs, partly in response to lower demand and revenue declines in our Bioprocess Division. As of December 31, 2009, we have substantially completed both phases of our global supply chain initiative and closed ten of the twelve manufacturing facilities included in our plans. One more facility will be closed in 2010, and we have decided not to close the remaining facility. We expect to incur approximately $2 million in 2010 in connection with finalizing the program and do not anticipate significant additional charges relating to this program going forward.

Results of Operations

REVENUES

Bioprocess Division

2009 VERSUS 2008

Bioprocess revenues of $925.8 million in 2009 increased $45.0 million, or 5 percent, compared to 2008. Foreign currency translation had a 3 percentage point adverse effect. Adjusting for this item, Bioprocess revenues increased 8 percent in 2009.

Revenue growth was primarily attributable to higher sales of our downstream bioprocessing products used in biopharmaceutical manufacturing. This was the result of higher spending levels by our large biotechnology customers in North America. These customers’ spending levels were adversely affected in 2008 by a reduction in their rate of monoclonal antibody production as a result of their evaluation of market demand for their products, and their efforts to lower their costs and to improve their working capital positions. In 2009, the level of manufacturing activities associated with monoclonal antibodies recovered, partially attributable to some customers ramping up manufacturing for new products in anticipation of new biologic drug approvals. Additionally, Bioprocess revenues increased from sales of products used in the H1N1 flu vaccine production, particularly in Europe and in the second half of 2009. We expect products used in vaccine production will continue to be an important driver for our revenue growth, although the high demand for our products created from H1N1 flu vaccine production will not repeat in 2010.

In addition to the biotechnology market sector, our Bioprocess Division’s core purification products sold into the plasma market grew by double digits, which was attributable to increased demand for plasma fractionation. To a lesser extent, the Bioprocess revenue increase was the

result of continued growth in process monitoring tools products. Demand for our on-site testing products is increasing, particularly our disposable Novaseptum^® product, as drug companies are adopting disposable sampling technology to monitor contamination earlier in the drug manufacturing process. Partially offsetting these increases was a decline in our upstream bioprocessing products resulting from lower end-market demand for certain drugs.

2008 VERSUS 2007

Bioprocess revenues of $880.8 million in 2008 increased $2.3 million, compared to 2007. Foreign currency translation had a 4 percentage point favorable effect. Adjusting for this item, Bioprocess revenues declined 4 percent in 2008. This decline was primarily attributable to lower sales of certain upstream and downstream bioprocessing products used in biopharmaceutical manufacturing, which was partially offset by increased sales of our process monitoring tools products. Lower sales of our upstream and downstream bioprocessing products were caused by lower spending by some of our largest biotechnology customers and weakening global economic conditions. We experienced significantly lower sales to these customers because of their reduced rate of monoclonal antibody production and the reduction of their inventory levels since the third quarter of 2007.

After experiencing a significant decline in the first half of the year, our Bioprocess Division stabilized in the second half of 2008 as some of our large key accounts increased their purchases. Sales of our disposable systems and components experienced strong growth year-over-year. Our process monitoring tools, which are used to test for biopharmaceutical contaminants, performed well in 2008. These products are sold to a diverse customer base, some of which were not adversely affected by the sales softness we experienced with our large biotechnology customers. In particular, we experienced increased demand for our Novaseptum^® products, a product line we acquired in our 2005 acquisition of Novaseptic.

Bioscience Division

2009 VERSUS 2008

Bioscience revenues of $728.6 million for 2009 increased $7.3 million, or 1 percent, compared to 2008. Foreign currency translation had a 2 percentage point adverse effect and our Guava acquisition had a 1 percentage point favorable effect on this revenue growth. Adjusting for these items, Bioscience revenues grew 2 percent in 2009. Revenue growth was primarily attributable to strong growth in protein research products, immunoassay products, and

laboratory water consumable products and services. Despite weak global economic conditions, government and private funding of academic research continued to be strong in 2009, which drove revenue growth. We completed our acquisition of Guava Technologies on February 20, 2009 and successfully expanded sales of our flow cytometry systems and newly developed reagents through our established distribution network.

Weakness in the global economy lowered demand for our laboratory instrumentation products and was the largest offset to Bioscience revenue growth in 2009. Revenue growth was also adversely affected by weak spending resulting from cost reductions in research functions of our large pharmaceutical customers. These customers have rationalized their drug pipelines, reassessed their research priorities, and focused on integrating acquisitions.

2008 VERSUS 2007

Bioscience revenues of $721.3 million for 2008 increased $68.2 million, or 10 percent, compared to 2007. Foreign currency had a 4 percent favorable effect on this revenue growth. Adjusting for this item, Bioscience revenues grew 6 percent, which was primarily driven by strong demand for our laboratory water products and services.

Bioscience revenue growth was reduced by 1 percent due to the elimination of a small product line. Successful new product introductions, execution of our sales and marketing initiatives, and continued expansion of our new e-commerce business platform all contributed to the revenue growth. The successful launch of new products such as the Milli-Q^® Integral and Milli-Q^® Advantage by our laboratory water business unit and strong growth in consumables and services contributed to the strong performance. Our biomarker and immunoassay products produced strong year-over-year growth as a result of new product introductions. Sales of our life science business unit’s biotools products also contributed to the revenue growth resulting from higher sales of analytical sample preparation, cell biology, and molecular biology products. This was a reflection of a healthy level of life science research activities in the protein research and cell biology markets.

REVENUES BY GEOGRAPHY

2009 VERSUS 2008

Revenues for 2009 in the Americas, Europe, and Asia/ Pacific were $660.0 million, $665.7 million, and $328.7 million, respectively. Excluding the effects of foreign

currency translation and acquisitions, revenues increased 7 percent in the Americas, 3 percent in Europe, and 6 percent in Asia/Pacific. The increase in the Americas was primarily the result of higher spending this year by our large biotechnology customers in North America. The increase in Europe was primarily driven by sales of our downstream bioprocessing and process monitoring products attributable to higher levels of H1N1 flu vaccine production and the higher demand for our on-site testing products. Protein research products, immunoassay products, and laboratory water consumable products and services also contributed to the year-over-year growth. The increase in Asia/Pacific was primarily driven by sales of our downstream bioprocessing products and process monitoring tools, especially in China and Singapore. Historically, our business in Asia/Pacific has been primarily driven by our Bioscience Division, but our Bioprocess Division has gained strong growth in the region as new biopharmaceutical production capacity increases. We continued to see investments into the biotechnology industry in the region by multi-national companies, governments, and contract manufacturing organizations. These positive trends in Asia/Pacific were offset by weak economic conditions in Japan and India during 2009.

2008 VERSUS 2007

Revenues for 2008 in the Americas, Europe, and Asia/ Pacific were $619.2 million, $683.3 million, and $299.7 million, respectively. Excluding the favorable foreign currency translation effect, revenues in the Americas, Europe and Asia/Pacific decreased 4 percent, increased 4 percent,

and increased 6 percent, respectively. The decrease in the Americas was primarily attributable to the lower sales to a handful of our largest biotechnology customers in the first half of 2008, which was offset by the strength of our laboratory water and drug discovery products. The increase in Europe was primarily driven by sales of our process monitoring tools products and laboratory water products and services, which was somewhat offset by a decline in sales of both upstream and downstream bioprocessing products in the 2008 second half. The increase in Asia/Pacific was primarily the result of strong sales of our laboratory water products and services, life science products, downstream bioprocessing products in Japan and China, and higher purchases from a large customer for a new manufacturing plant in Singapore.

GROSS PROFIT MARGIN

2009 VERSUS 2008

Gross profit increased $54.1 million, or 6 percent, compared to 2008. Gross profit margin improved from 53 percent of revenues to 55 percent of revenues this year. The primary drivers of the gross profit increase were lower costs associated with our global supply chain initiatives, favorable foreign currency translation, productivity improvements, and a favorable price impact. We incurred charges associated with our global supply chain initiative (primarily employee separation costs, facility closure costs, and accelerated depreciation) amounting to $11.7 million and $16.5 million in 2009 and 2008, respectively. The year-over-year decrease in these charges were primarily attributable to lower employee separation and related expenses in 2009. In 2010, we expect to complete our global supply chain initiative and to incur approximately $2 million of planned additional costs. The favorable foreign currency impact was primarily the result of a weaker Euro and a stronger Japanese Yen in 2009, compared to

2008. When translated into U.S. dollars, our Irish and French manufacturing operations represented a lower proportion of our total manufacturing costs in 2009 as a result of the weaker Euro. Generally, when the Japanese Yen strengthens against the U.S. dollar and/or the Euro, our gross margin is favorably impacted because substantially all of our manufacturing activities are in the United States, Ireland, and France. Full year amortization of purchased intangibles affecting gross profit was $8.1 million, compared to $9.4 million in 2008.

These favorable effects were offset by an unfavorable product mix, higher incentive compensation costs, lower manufacturing volumes, inventory write-downs, and acquisition inventory fair value adjustments. The lower manufacturing volumes were the result of inventory reductions in connection with our working capital initiative improvements implemented during the year. As part of our working capital initiative, we also wrote off inventory items that were related to certain low volume and unprofitable product lines.

The higher incentive compensation costs reflect improved year-over-year operating results. The unfavorable product mix reflected increased sales of lower margin chromatography media and hardware products and reduced sales of higher margin cell culture supplement products.

2008 VERSUS 2007

Gross profit increased $42.3 million, or 5 percent, compared to 2007. The primary drivers of the increase were higher revenues, improved business and product mix, and productivity improvements. Bioscience revenues, which have higher gross profit margins, represented a larger percentage of our revenues, while sales of large Bioprocess systems, chromatography media and insulin products with lower gross profit margins represented less of our sales mix. Additionally, the absence of Serologicals business acquisition inventory fair value adjustments amounting to $11.1 million and acquisition integration costs amounting to $2.7 million contributed to the increase in 2008. Somewhat offsetting increased gross profit margin was the adverse effect of a stronger Euro and costs associated with our global supply chain initiatives. When translated into U.S. dollars, our Irish and French manufacturing operations represented a higher proportion of our total manufacturing costs in 2008. We incurred charges associated with our global supply chain initiative (primarily employee separation costs, facility closure costs, and accelerated depreciation) amounting to $16.5 million and $11.3 million in 2008 and 2007, respectively. The year-over-year increase in these charges were primarily attributable to higher employee separation and related expenses that we were required to accrue for certain foreign employees when we announced the facility closure plans in September 2008.

Full year amortization of purchased intangibles affecting gross profit was $9.4 million, compared to $9.5 million in 2007. Gross profit margin for 2008 remained relatively flat at 53 percent compared to 2007.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

2009 VERSUS 2008

Selling, general and administrative (“SG&A”) expenses increased $7.0 million, or 1 percent, compared to 2008. Excluding the favorable effect of foreign currency translation, SG&A expenses increased $18.7 million, or 4 percent. The increase was primarily attributable to increased employee-related costs driven by: higher incentive compensation costs; salary increases; higher stock market prices associated with our unfunded Supplement Savings and Retirement Plan; higher stock-based compensation expenses associated with changes made to equity compensation plans in prior years; and the absence of a curtailment gain in 2008 related to our postretirement benefits plan. Additionally, we completed the acquisitions of Guava Technologies, BioAnaLab and the remaining 60 percent ownership of our India joint venture in 2009, which resulted in acquisition and integration costs. We did not complete any business acquisitions in 2008. These increases were offset by the absence this year of employee separation charges incurred as a result of market conditions that caused revenue declines in our Bioprocess Division and a fixed asset impairment loss related to an idle facility. Amortization expense was also lower in 2009 as the economic benefit of purchased intangibles decreases with the passage of time. Full year amortization of purchased intangibles affecting SG&A was $49.2 million, compared to $53.7 million in 2008.

2008 VERSUS 2007

SG&A expenses increased $30.0 million, or 6 percent, compared to 2007. Foreign currency translation accounted for a 3 percentage point year-over-year increase. Other primary drivers of the increase were higher employee compensation, separation expenses associated with our ongoing efforts to streamline operations, increased stock-based compensation expense, a fixed asset impairment loss, and higher amortization of intangible assets. Stock-based compensation expense of $17.3 million in 2008 increased $5.5 million, or 46 percent, over 2007 as a result of changes we made to our equity compensation plans in 2004. The fixed asset impairment loss amounted to $5.8 million and was related to an idle facility. These costs were partially offset by a curtailment gain of $2.7 million related to amendments to our U.S. postretirement benefits plan. Full year amortization of purchased intangibles affecting SG&A was $53.7 million, compared to $48.9 million in 2007.

RESEARCH AND DEVELOPMENT EXPENSES

2009 VERSUS 2008

R&D increased $12.0 million, or 12 percent, compared to 2008. Excluding the effect of favorable foreign currency translation, R&D expenses increased $13.4 million, or 13 percent. The increase was primarily the result of increased employee related costs, higher investments in R&D projects, strategic investments and payments to third-party technology partners to support innovation, and the inclusion this year of Guava R&D expenses. A component of our innovation strategy is to enhance our internal R&D capabilities through investments in technology collaborations and license arrangements that will help us to develop innovative new products and capture greater value for our customers. The strength of our business provided us the flexibility to continue to make strategic investments during the economic downturn which will benefit future growth.

2008 VERSUS 2007

R&D expenses decreased $4.4 million, or 4 percent, compared to 2007. The decreases were primarily the result of the timing of project spending. Our 2008 R&D expenses also decreased $1.4 million because of higher R&D credits resulting from a change in legislation.

INTEREST INCOME/EXPENSE

INTEREST INCOME/EXPENSE

$ in millions

2009 VERSUS 2008

Interest expense decreased $11.8 million, or 17 percent, compared to 2008. Excluding the effect of foreign currency translation, interest expense decreased $12.7 million, or 18 percent. The decrease was primarily the result of lower overall debt balances as we continued to repay our debt and, to a lesser extent, lower base rates under our revolver borrowings. Our adoption of the new accounting standard for convertible debt that may be settled in cash upon conversion added a non-cash interest expense of $14.7 million and $13.7 million for 2009 and 2008, respectively. Our revolving credit facilities are comprised of floating rate borrowings. Increases or decreases to these rates would cause increases or decreases to our interest expense, respectively.

2008 VERSUS 2007

Interest expense decreased $8.4 million, or 11 percent, compared to 2007. The decrease was primarily the result of lower debt balances year over year. This was somewhat offset by the effect of a stronger Euro on our Euro-denominated debt. Our adoption of the new accounting standard for convertible debt that may be settled in cash upon conversion added a non-cash interest expense of $13.7 million and $12.7 million for 2008 and 2007, respectively.

PROVISION FOR INCOME TAXES

We provide for U.S. income taxes on the earnings of foreign subsidiaries unless they are considered indefinitely invested outside the U.S. We elected to treat the earnings of our Ireland, the United Kingdom (“UK”), and Sweden subsidiaries as indefinitely invested outside the U.S. These elections were made based on our operating plans and foreign debt service requirements. Our effective income tax rates for 2009, 2008, and 2007 reflected the tax benefit associated with lower tax rates on earnings from these three subsidiaries.

EFFECTIVE INCOME TAX RATE

2009 VERSUS 2008

The increase in the effective tax rate in 2009 compared to 2008 was primarily attributable to the fact that profits in our lower tax rate jurisdictions constituted a lower percentage of total consolidated profit before income taxes.

The lower income tax rates from our operations in Ireland, Sweden, and the UK resulted in 14.4 percentage point reduction in our effective tax rate, compared to 17.2 percentage point reduction in 2008. During 2009, three significant items provided a discrete tax benefit to the effective tax rate. We recorded $2.8 million of previously unrecognized tax benefits as a result of statute of limitations closures. We recognized a $2.0 million tax benefit associated with realization of R&D tax credits. Our effective income tax rate also benefited from the $8.5 million non-taxable gain on the Guava acquisition.

Over the next 12 months, we may need to record up to $3.3 million of previously unrecognized tax benefits in the event of statute of limitations closures.

2008 VERSUS 2007

The higher effective tax rate in 2008 compared to 2007 was caused by a shift in the jurisdictional mix of our profits to higher tax rate jurisdictions and less previously unrecognized tax benefits. Lower income tax rates from our Ireland, the UK and Sweden subsidiaries resulted in a 17.2 percentage point reduction in our effective tax rate, compared to 22.7 percentage point reduction in 2007. During 2008, we recorded $1.6 million of previously unrecognized tax benefits as a result of statute of limitations closures. We also released valuation allowances on certain R&D tax credits amounting to $1.1 million as a result of a tax law change in the United States.

Another main reason for our lower effective tax rate in 2007 was the recognition of $11.9 million of previously unrecognized tax benefits as a result of statute of limitations closures and a pretax income mix favoring lower tax rate jurisdictions.

In the normal course of business, we are examined by various tax authorities, including the Internal Revenue Service (the “IRS”). In 2008, the IRS concluded its examination of years 2004 and 2005, without any significant adjustments.

OPERATING PROFIT, NET INCOME AND DILUTED EARNINGS PER SHARE

OPERATING PROFIT, NET INCOME AND DILUTED EARNINGS PER SHARE

$ in millions, except per share data

* See non-GAAP reconciliation on page 63 for more information.

2009 VERSUS 2008

Operating profit increased $35.1 million, or 15 percent, compared to 2008 primarily as a result of higher revenues, operational efficiencies and favorable effect of foreign currency translation. These increases were partially offset by higher employee-related costs and higher investments in research and development. On a GAAP basis, the 29 percent increase in net income attributable to Millipore was the result of higher operating profit, the $8.5 million gain on the Guava acquisition, and lower interest expense. The favorable effects were partially offset by a higher tax rate in 2009. On a non-GAAP basis, the 12 percent increase in net income attributable to Millipore was the result of higher operating profit and lower interest expense. The favorable effects were partially offset by a higher tax rate in 2009.

2008 VERSUS 2007

Operating profit increased $16.8 million, or 8 percent, compared to 2007 primarily as a result of higher gross profit and lower R&D expenses, offset by higher SG&A expenses and unfavorable effect of foreign currency translation. On a GAAP basis, the 7 percent increase in net income attributable to Millipore and 6 percent increase in diluted earnings per share were attributable to higher operating profit and lower interest expense, partially offset by a higher tax rate in 2008. On a non-GAAP basis, the 8 percent increase in net income attributable to Millipore and 7 percent increase in diluted earnings per share were attributable to higher operating profit and lower interest expense.

Capital Resources and Liquidity

The following table shows information about our capitalization as of the dates indicated:

NET DEBT*

$ in millions

* Non-GAAP. See page 62 for more information.

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements will be to fund operations, capital expenditures, investments in businesses, debt service, and share repurchase. Our primary sources of liquidity are internally generated cash flows and borrowings under our revolving credit facility. Significant factors affecting the management of our ongoing cash requirements are the adequacy of available bank lines of credit and our ability to attract long-term capital with satisfactory terms. The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, a decrease in demand for our products, our ability to integrate acquisitions, deterioration in certain financial ratios, and market changes in general.

The global economic recession had an adverse impact on financial market activities including, among other things, volatility in security prices, diminished liquidity and credit availability, and declining valuations of certain investments. Except for slower growth in revenues from certain products, there has not been any significant negative impact to our financial position, results of operations, or liquidity to date. There can be no assurance, however, that changing circumstances will not affect our future financial position, results of operations, or liquidity.

The cost of additional or replacement financing is partly a function of our debt to capitalization levels, credit standing, and financial market conditions. Our credit ratings are reviewed regularly by major debt rating agencies such as Standard & Poor’s and Moody’s Investors Service. The chart below summarizes our current ratings.

We believe our future operating cash flows will be sufficient to meet our future operating and investing cash needs. The availability of borrowings under our primary revolving credit

facility and our ability to obtain equity financing provide additional potential sources of liquidity should they be required. We intend to utilize excess cash generated from our operations to fund future acquisitions while preserving an appropriate level of cash needed for our operations. We may from time to time seek to retire or purchase our outstanding obligations. We may also seek to repurchase shares of our common stock. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions, and other factors. The amounts involved may be material.

The repatriation of cash balances from certain of our subsidiaries could have adverse tax consequences. However, these cash balances are generally available without legal restrictions to fund ordinary business operations. We have transferred, and will continue to transfer, cash from our subsidiaries to us and to other international subsidiaries when it is necessary and cost effective to do so.

We anticipate the need to obtain fixed-rate debt on or before December 1, 2011 as a result of certain put provisions of our convertible notes. In August 2009, we entered into forward starting interest rate swap agreements with a total notional amount of $300 million. The objective of these interest rate swaps is to hedge the variability of the forecasted interest payments on this anticipated fixed-rate debt. The fixed rate on these interest rate swap agreements is 4.6225 percent. At December 31, 2009, the fair value of these interest rate swap agreements was a gain of $4.9 million, which was recognized in accumulated other comprehensive income. The net gain or loss from these cash flow hedges will fluctuate as interest rates change.

CASH FLOWS

The following table summarizes our sources and uses of cash over the periods indicated:

SOURCES AND USES OF CASH

$ in millions

* Non-GAAP. See page 62 for more information.

OPERATING CASH FLOWS

Cash provided by operating activities was $370.2 million for 2009 and was primarily attributable to our net income

of $179.2 million, non-cash items totaling $163.4 million (primarily depreciation and amortization expenses, stock-based compensation expense, and debt discount amortization), and a working capital decrease of $27.6 million. Our working capital decrease was primarily the result of improvements in our cash collection and inventory management processes and change in income taxes payable. Compared to the prior year, we achieved a 7 day improvement in days sales outstanding to 59 days. We implemented a new collections software and streamlined our working practices using Lean Six Sigma^® methodologies in 2009. These resulted in better customer communication and faster cash collection. Additionally, we achieved an 11 day improvement in our days supply in ending inventory to 118 days resulting from our global supply chain initiatives that contributed to reductions in lead and cycle times, manufacturing lot sizes, and safety stock levels. Lastly, our income taxes payable balance increased, which was attributable to a significant prepaid income tax balance in 2008 resulting from a change in R&D tax credit regulations and jurisdictional profit mix. Partially offsetting these working capital decreases was a $10.5 million discretionary pension funding contribution to our U.S pension plan, a self insurance funding prepayment of $5.0 million, and accelerated supplier payments to take advantage of early vendor payment discounts.

INVESTING CASH FLOWS

Cash used in investing activities was $107.3 million for 2009. We paid $72.1 million for capital expenditures and $29.9 million for the acquisitions of Guava and BioAnaLab, net of cash acquired. We expect our 2010 capital expenditures will be approximately $80 million.

FINANCING CASH FLOWS

Cash used for financing activities was $220.8 million for 2009. We acquired the remaining 60 percent ownership of our joint venture in India for $58.1 million. Net repayments of our borrowings under our primary revolving credit facility amounted to $208.2 million and net borrowings of short-term debt amounted to $34.9 million.

In 2009, we fully repaid all borrowings under our primary revolver. Additionally, we received proceeds of $13.2 million from the exercises of employee stock options and paid dividends of $2.6 million to our joint venture partner.

FINANCING COMMITMENTS

Short-term debt

Short-term debt consisted of borrowings under our operating bank facilities and two short-term revolving credit facilities in Japan. These credit facilities provide for cumulative borrowings of ¥7.0 billion, or $75.3 million, with an interest rate of TIBOR plus an applicable margin. Interest is payable at the end of an interest period based upon the term of the borrowing. These credit facilities expire in December 2010 and are subject to annual renewal at terms consistent with the initial agreements. As of December 31, 2009, we had ¥3.1 billion, or $33.5 million, available for borrowing under these credit facilities. We are not required to comply with any debt covenants under these agreements.

Primary revolving credit facility

We have a five-year unsecured revolving credit facility (the “Revolver”) that expires in June 2011.

The Revolver provides for a maximum borrowing of €465.0 million, or $665.8 million. We may elect to increase the credit facility by an amount not in excess of €130.0 million, or $186.1 million. We may prepay any outstanding borrowings in whole or in part without premium or penalty. We are required to pay an unused commitment fee ranging between 0.0675 percent and 0.60 percent annually based on the Revolver’s debt rating.

We are required to maintain certain leverage and interest coverage ratios as set forth in the Revolver agreement. In general, the leverage ratio is calculated by dividing our total outstanding indebtedness at December 31, 2009 by our cumulative cash earnings for the twelve months ended December 31, 2009. The interest coverage ratio is calculated by dividing our cumulative cash earnings for the twelve months ended December 31, 2009 by our

cumulative gross interest expense for the twelve months ended December 31, 2009.

The following table summarizes the financial covenant requirements as of December 31, 2009 and thereafter and our compliance with these covenants as of December 31, 2009:

REVOLVER AGREEMENT COVENANTS

Our ability to continue to comply with these covenants will depend primarily on the success in growing our business and generating strong operating cash flows. Future compliance with the covenants may be adversely affected by various economic, financial, and industry factors. Noncompliance with the covenants would constitute an event of default under the Revolver, allowing the lenders to accelerate repayment of any outstanding borrowings at this time.

As of December 31, 2009, we had no borrowings outstanding under the Revolver. The borrowing capacity allowed by our debt covenants under the Revolver was $665.8 million at December 31, 2009.

3.75% convertible senior notes due 2026

In June 2006, we issued $565.0 million in aggregate principal amount of convertible senior notes (the “Convertible Notes”) in a private placement offering. The Convertible Notes will mature on June 1, 2026. We used the net proceeds from this offering to complete the acquisition of Serologicals on July 14, 2006. The Convertible Notes bear interest at 3.75 percent per annum, payable semi-annually in arrears on June 1 and December 1 of each year. Commencing with the six-month period beginning on December 1, 2011, if the average trading price of the Convertible Notes for the five consecutive trading days preceding such six-month periods equals 120 percent or more of the principal amount, contingent interest will

accrue at the rate of 0.175 percent of the average trading price of the Convertible Notes.

The Convertible Notes are our senior unsecured obligations and rank equally with all of our existing and future senior unsecured indebtedness. The Convertible Notes are effectively subordinated to all of our existing and future secured indebtedness and all existing and future liabilities of our subsidiaries, including trade payables.

Holders of the Convertible Notes may convert their notes into cash and, if applicable, shares of our common stock prior to June 1, 2026 under certain conditions. The Convertible Notes will be convertible at any time from November 1, 2011 through December 1, 2011 and any time on or after June 1, 2024. Upon conversion, the Convertible Notes will be converted into cash for the principal amount and shares of our common stock for the conversion premium, if any, based on an initial conversion rate of 11.0485 shares per $1,000 principal amount (which represents an initial conversion price of approximately $90.51 per share), subject to adjustments.

On or after December 1, 2011, we have the option to redeem the Convertible Notes at a redemption price equal to 100 percent of the principal amount of the notes, plus accrued but unpaid interest. On each of December 1, 2011, June 1, 2016 and June 1, 2021, holders of the Convertible Notes have the option to require us to purchase all or a portion of their notes at a purchase price in cash equal to 100 percent of the principal amount of the notes, plus accrued but unpaid interest.

Although we are not required to maintain any specified financial ratios under the Convertible Notes agreement, we will be considered in default if we fail to fulfill our conversion or redemption obligations, make required interest payments, provide notice to holders of the Convertible Notes in certain specified circumstances, or cure our default on any of our indebtedness or that of our subsidiaries in the aggregate principal amount of $50 million or more. If an event of default has occurred and is continuing, the principal amount of the Convertible Notes plus interest thereon may become immediately due and payable. We are currently in compliance with the covenant restrictions.

5.875% senior notes due 2016

In June 2006, we issued €250.0 million in aggregate principal amount of 5.875 percent senior notes (the “Euro Notes”) due 2016. Interest is payable semi-annually in arrears on June 30 and December 30 of each year. The Euro Notes were issued at 99.611 percent of the principal amount, which resulted in an original issue discount of €1.0 million. The Euro Notes are our senior unsecured obligations and rank equally with all of our existing and future senior unsecured indebtedness.

Upon the occurrence of any change in control, holders of the Euro Notes may require us to repurchase all of their Euro Notes for a cash price equal to 101 percent of the principal amount, plus accrued and unpaid interest thereon. Before June 30, 2016, we may, at our option, redeem the Euro Notes, in whole or in part, for cash, at a redemption price equal to 100 percent of the principal amount of the Euro Notes we redeem, plus an applicable “make-whole” premium. In addition, upon the occurrence of certain tax events in the United States, we may redeem, at our option, in whole but not in part, at a redemption price equal to the principal amount, plus accrued and unpaid interest.

The indenture for the Euro Notes places certain restrictions on our ability to create, incur, assume or suffer liens on our manufacturing plants and other principal facilities in the United States and ability to enter into certain sale leaseback transactions. We would also be considered in default if we fail to fulfill our redemption obligations, make required interest payments, provide notice to holders of the Euro Notes in certain specified circumstances, or cure our default on any of our indebtedness or that of our subsidiaries in the aggregate principal amount of $50 million or more. If an event of default has occurred and is continuing, the principal amounts of the Euro Notes plus any accrued interest thereon may become immediately due and payable. We are currently in compliance with the covenant restrictions.

Long-term debt obligations include estimated interest payments on our 3.75 percent Convertible Notes and our 5.875 percent Euro Notes for the respective periods presented above.

We maintain various defined benefit pension and postretirement plans for the benefit of our employees. At December 31, 2009, our U.S. pension plan and postretirement benefit plans were under-funded by $8.3 million and $3.0 million, respectively. At December 31, 2009, our foreign retirement plans were under-funded by $18.7 million. We anticipate minimum funding for these plans will be approximately $2.0 million in 2010. Amounts included in the table above for employee pension and postretirement medical plans reflect projected benefit payments. Our future pension expense and pension liabilities will be affected by fluctuations in future discount rates as well as the fair market value of assets used to fund these plans. Additionally, we intend to terminate our U.S. pension plan when it is cost effective to do so. Upon settlement, we will be required to make a final cash payment which may be significant. We cannot reasonably estimate the cash outflow requirements as the amounts will not be determinable until the actual settlement occurs.

Our non-cancellable purchase obligations include obligations related to the future purchase of goods and services, capital lease obligations, and other long-term liabilities reflected on our balance sheet.

The above table does not reflect unrecognized tax benefits of $26.1 million, the timing of which is uncertain. We cannot make reasonably reliable estimates of the period of cash settlement with tax authorities.

Critical Accounting Estimates

Preparation of our financial statements requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. Note 2 to the consolidated financial statements describes the significant accounting policies used in the preparation of our consolidated financial statements. Management believes the most complex and sensitive judgments result primarily from the need to make estimates about the effects of matters that are inherently uncertain and are significant to the consolidated financial statements. The most significant areas involving management estimates, judgments, and assumptions are described below. Actual results in these areas could differ from management’s estimates.

REVENUE RECOGNITION

Revenue from the sale of products is recognized when we meet all of the criteria for revenue recognition in financial statements. These criteria include:

evidence of an arrangement is in place;

related prices are fixed or determinable;

delivery or performance has occurred; and

collection of the resulting receivable is reasonably assured.

Customer purchase orders or sales agreements evidence our sales arrangements. These purchase orders and sales agreements specify both selling prices and quantities, which are the basis for recording sales revenue. Trade terms for the majority of our sales contracts indicate that title and risk of loss pass from us to our customers when we ship products from our facilities, which is when revenue is recognized. Revenue is deferred until our products arrive at customers’ facilities in situations where trade terms indicate that title and risk of loss pass from us to the customers upon their receipt of our products. We perform ongoing credit evaluations of our customers and ship products only to customers that satisfy our credit evaluation. We also maintain allowances for doubtful accounts for estimated losses resulting from our customers’ inability to make required payments. We have not experienced any significant deterioration in the credit quality of our customers or the age of our customer receivables as a result of the global economic recession.

Consumable and hardware products account for over 90 percent of our total consolidated revenues and are typically sold with standard terms and conditions. Revenues for these products are generally recognized upon shipment or delivery to the customers. In instances where we sell filtration systems and laboratory instrumentation products with a related installation obligation, we generally recognize revenue related to these products when title passes and recognize revenue related to the installation when installation is complete. The allocation of revenue between the product and the installation service is based on relative fair value at the time of sale.

In limited cases, our customers may require site acceptance testing for certain customized products built to customers’ specifications. Revenues on these products are deferred upon shipment and are recognized when site acceptance testing is completed.

Revenue from service arrangements is recognized when the services are provided or over the contractual period. Installation and maintenance service revenues are recognized when the site service visit is completed. Validation testing services revenue is recognized when the contracted

study is completed and accepted by the customer. Sample analysis services revenue is recognized as each sample analysis is completed. Assay development and assay validation service revenue is recognized proportionally as contractually defined deliverables are provided to the customer. Revenue related to maintenance and warranty service contracts is recognized ratably over the contractual period or as the services are performed, based on the terms of the arrangement.

License and royalty revenue is recognized when the amounts are determinable and we have fulfilled our obligations under the applicable agreement. This generally occurs when cash payments are received or licensed sales are reported to us.

INVENTORY VALUATION

Significant judgment is required to estimate the net realizable value of our inventory. Our product life cycle is generally a minimum of 2 years and may be in excess of 20 years. Therefore, we generally rely on recent historic usage, expiration dates, and estimated future demand in estimating the realizable value of our inventory. Finished goods and components that are determined to be obsolete are written off when such determination is made. In certain cases, such as for newly introduced products and overstocked products, estimated future demand is considered in establishing inventory write-downs. Raw material and work-in-process inventories are also reviewed for obsolescence and alternative or future use based on reviewing manufacturing plans, estimated future demand, and market conditions.

In situations where it is determined that work-in-process inventories cannot be converted into finished goods, the inventories are written down to net realizable value. Inventory at December 31, 2009 reflected cumulative net realizable value write-downs of $35.6 million. Should it be determined that write-downs are insufficient, we would be required to record additional inventory write-downs, which would have a negative impact on gross profit margin. Once recorded, inventory valuation provisions are not subsequently reversed unless the related inventory items are sold to third parties.

VALUATION OF LONG-LIVED ASSETS

Valuation of certain long-lived assets including property, plant and equipment, intangible assets, and goodwill requires significant judgment. Assumptions and estimates are used in determining the fair value of assets acquired and liabilities assumed in a business acquisition. A significant portion of the purchase price in our acquisitions is assigned to intangible assets and goodwill. Assigning value to intangible assets requires that we use significant judgment in determining the fair value and whether such intangibles assets are amortizable. For intangible assets, we exercise judgment in determining the period and the method by which the intangible assets will be amortized. We utilize commonly accepted valuation techniques, such as the income approach and the cost approach, as appropriate, in establishing the fair value of long-lived assets. Typically, key assumptions include projected revenue and expense levels used in establishing the fair value of business acquisitions as well as discount rates based on an analysis of our weighted average cost of capital, which is adjusted for specific risks associated with the assets. Changes in the initial assumptions may lead to changes in amortization expense recorded in our future financial statements.

We assess the carrying value of intangible assets and property, plant and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could

trigger an impairment review include, but are not limited to, the following:

significant underperformance relative to expected historical or projected future operating results;

significant negative industry or economic trends; or

significant changes or developments in strategy or operations that negatively affect the utilization of our long lived-assets.

Should we determine that the carrying value of long-lived tangible and intangible assets may not be recoverable, we will measure any impairment based on a projected discounted cash flow method using a discount rate determined by management to be commensurate with the risk inherent in our current business model. We may also estimate fair value based on market prices for similar assets, as appropriate. Significant judgments are required to estimate future cash flows and to select the appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value for these assets.

We perform annual reviews in our second quarter for impairment of goodwill and whenever events or changes in circumstances would more likely than not reduce the fair value of a reporting unit below its carrying value. Goodwill may be considered to be impaired if we determine that the carrying value of a reporting unit, including goodwill, exceeds the reporting unit’s fair value. Our reporting units are our Bioprocess and Bioscience operating segments. Assessing the impairment of goodwill requires us to make assumptions and judgments regarding the fair value of the net assets of our reporting units. We estimate the fair value of our reporting units using a combination of valuation techniques, including discounted cash flows and cash earnings multiples, and compare the values to our estimated enterprise value. Our annual impairment test did not indicate any impairment on our goodwill. Terminal growth rate and weighted average cost of capital are significant assumptions in our analysis. Adjusting those assumptions by 10% would not have had an impact on the results of our impairment analysis.

STOCK-BASED COMPENSATION

Stock-based compensation expense is estimated as of the grant date based on the fair value of the stock-based compensation awards, which include stock options and restricted stock units. We estimate the fair value of our stock options using the Black-Scholes option-pricing model and the fair value of our restricted stock units based on the quoted market price of our common stock at the date of grant. Estimating the fair value of stock options requires judgment including the expected term of our stock options, volatility of our stock, expected dividends, and risk-free interest rates over the expected term of the options. The expected term represents the average time that options are expected to be outstanding and is estimated based on the historical exercise, post-vesting cancellation and expiration patterns of our stock-based awards. The expected volatility rates are estimated based on historical volatilities of our common stock over a period of time that approximates the expected term of the options. Expected dividends are estimated based on our dividend history as well as our current projections. The risk-free interest rate for periods approximating the expected terms of the options is based on the U.S. Treasury yield curve in effect at the date of grant.

We recognize stock-based compensation expense in our consolidated statement of operations over the requisite service period of the awards, which generally represents the vesting period, net of estimated forfeitures. Forfeiture rates are estimated based on historical pre-vesting forfeiture history and are updated on a quarterly basis to reflect actual forfeitures of unvested awards and other known events. For stock-based compensation awards that vest over time based on employment, we recognize the associated compensation expense on a straight line basis over the requisite service period. For performance-based restricted stock units, we recognize the related compensation expense ratably over the vesting period when it is probable that the performance targets are expected to be achieved based on management’s projections. We evaluate, on a quarterly basis, the probability that the target performance goals will be achieved, if at all, and the anticipated level of achievement.

In 2009, we recognized stock-based compensation expense on restricted stock units, stock options, and performance-based restricted stock units of $17.3 million, $7.3 million, and $2.2 million, respectively.

INCOME TAXES

We prepare and file tax returns based on our interpretation of tax laws and regulations and record estimates based on these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities, which may result in future tax, interest, and penalty assessments by these authorities. Inherent uncertainties exist in estimates of many tax positions because of changes in tax law resulting from legislation, regulation, and tax court rulings in various tax jurisdictions. Because significant judgment is required in determining our worldwide provision for income taxes, we periodically assess our income tax positions and record tax benefits for all years subject to examination based on our evaluation of the facts, circumstances, and information available at the reporting date. For those tax positions with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has all relevant information, we record a tax benefit. For those income tax positions that are not likely to be sustained, no tax benefit is recognized in the consolidated financial statements. We believe that our estimates for uncertain tax positions are appropriate and sufficient to pay assessments that may result from examinations of our tax returns. Any reduction of these contingent liabilities or additional assessment would increase or decrease income, respectively, in the period such determination is made. As of December 31, 2009, we had $26.1 million unrecognized tax benefits. In 2009, we reduced our uncertain tax positions by $2.8 million as a result of completion of tax examinations and statute of limitations closures. We recognize both accrued interest and penalties related to unrecognized tax benefits in income tax expense. Over the next 12 months, we may need to record up to $3.3 million of previously unrecognized tax benefits in the event of statute of limitations closures.

We are a worldwide business operating in numerous countries under many legal forms and, as a result, are subject to the jurisdiction of numerous domestic and non-U.S. tax authorities as well as tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the interpretation of the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law, and the sources and character of income and tax credits. Changes

in tax laws, regulations, agreements and treaties, currency exchange restrictions, or our profitability in each taxing jurisdiction could have an impact upon the amount of our provision for income taxes and our net income. We provide for U.S. income taxes on the earnings of foreign subsidiaries unless they are considered indefinitely invested outside the U.S. We elected to treat the earnings of our Ireland, the United Kingdom, and Sweden subsidiaries as indefinitely invested outside the U.S. These elections were made based on our operating plans.

We have recorded valuation allowances against certain of our deferred tax assets. These primarily relate to federal tax research credits, state tax credits, and net operating loss carryforwards in certain jurisdictions. We do not consider unidentified tax planning strategies in evaluating whether we would be able to more likely than not benefit from our deferred tax assets. Therefore, we may need to reverse valuation allowances in the future if these jurisdictions become profitable or we execute tax planning strategies. This would result in a reduction to our provision for income taxes. At December 31, 2009, we had valuation allowances of $1.3 million related to federal research credits and $27.0 million related to state tax credits and net operating loss carryforwards.

EMPLOYEE RETIREMENT PLANS

In the U.S., we sponsor a pension plan covering substantially all employees who had joined Millipore prior to January 1, 2006 and met certain eligibility requirements.

The pension plan was frozen as of December 31, 2006, after which no benefits accrued. All participants’ accrued benefits under the pension plan became fully vested as of that date. Several key assumptions are used in calculating the expense and liability of the pension plan, typically on an annual basis. The most significant assumptions include the discount rate and the expected return on plan assets. In selecting the expected return on plan assets, we considered the average rate of earnings expected on the funds invested or to be invested to provide for the benefits under the pension plan. This included considering the asset allocations and the expected returns likely to be earned on

similar investments over the life of this plan. The assumed discount rate is intended to approximate the actual rate at which benefits could effectively be settled. We used the Citigroup Pension Discount Curve as the benchmark rate for estimating our discount rate for pension expense. In addition, we update, as needed, other assumptions used in determining the expense and liabilities of the plan, such as withdrawal and mortality assumptions based on the average age grouping of our plan participants and updated mortality tables published by the Society of Actuaries. The actuarial assumptions used by us may differ materially from actual results due to changing market and economic conditions, higher or lower withdrawal rates, or longer or shorter life spans of the participants. These differences may have a significant effect on the amount of pension expense recorded by us in future years. During 2009, we recognized our pension expense using a discount rate of 6.0 percent and an expected return on plan assets of 7.5 percent. Although they were the most sensitive assumptions, a 0.5 percentage point change in either assumption would be immaterial to our results of operations and financial position.

We intend to terminate our U.S. pension plan when it is cost effective to do so. Upon settlement of the pension liabilities at the time of plan termination, we expect to recognize settlement losses in our consolidated statement of operations and report cash payments as cash outflows from operating activities in our consolidated statement of cash flows, which may be significant.

We can not reasonably estimate the size of such losses and cash outflows because such amounts will be determined using market interest rates and funded status of our pension plan at the time of actual plan termination.

In certain foreign subsidiaries, we also sponsor defined benefit pension plans for our employees. Accounting and reporting for these plans requires the use of country specific assumptions for discount rates, expected returns on plan assets, and rates of compensation increases. We apply a consistent methodology to determine the key assumptions. Our discount rates are based on high quality bond indices for durations that approximate the average remaining service periods of our plan participants in each country. We select expected long-term rates of return on plan assets based on the average rate of earnings expected on funds invested or to be invested to provide for the benefits under these plans. Although the most sensitive assumptions used in calculating the expense and liability of our foreign pension plans are the discount rate and the expected rate of return on plan assets, a 0.5 percentage point change in either assumption would be immaterial to our results of operations and financial position.

Market Risk

We are exposed to market risks, which include foreign currency exchange rate risk, interest rate risk, and credit risk. We manage these market risks through our normal financing and operating activities and, when appropriate, through the use of derivative financial instruments.

FOREIGN CURRENCY EXCHANGE RATE RISK

We are exposed to foreign currency exchange rate risk inherent in revenues, net income, and assets and liabilities denominated in currencies other than the U.S. dollar. The potential change in foreign currency exchange rates represents a substantial risk to us because approximately 66 percent of our business was conducted outside of the United States for 2009, generally in foreign currencies. Our primary risk management strategy is to use forward exchange contracts to hedge certain foreign currency

exposures. The intent of this strategy is to offset gains and losses that occur on the underlying exposures with gains and losses resulting from the forward exchange contracts that hedge these exposures. Principal hedged currencies include the Japanese Yen, Euro, Australian Dollar, and Canadian Dollar. Gains and losses resulting from changes in the value of the derivatives are either recognized currently in earnings or reported in other comprehensive income, a separate component of equity, depending on whether the derivative has been designated and qualifies as an effective hedge.

As of December 31, 2009, we had open forward exchange contracts designated as cash flow hedges of forecasted intercompany sales with total U.S. dollar equivalent notional amounts of approximately $174.0 million. These forward exchange contracts are generally short-term in nature and mature through January 2011. Based on our analysis, a hypothetical adverse foreign exchange rate movement of 10 percent against our forward exchange contracts would have resulted in a net loss in fair value of these contracts of approximately $18.4 million. In addition, we also hold forward exchange contracts to mitigate the impact of foreign exchange risk related to certain foreign currency denominated receivable and payable balances. Changes in fair value of these forward exchange contracts are recorded through current earnings because these instruments do not qualify for hedge accounting. As of December 31, 2009, the U.S. dollar equivalent notional amounts of the forward exchange contracts related to foreign currency denominated receivable and payable balances totaled $209.1 million. The periods of these forward exchange contracts typically is less than three months. The fair value of these forward exchange contracts was a net gain of $1.1 million at December 31, 2009.

Our risk management policy allows for hedging our net investments in foreign subsidiaries, using both derivative and non-derivative instruments. In June 2006, we issued €250.0 million of Euro-denominated senior notes, which gives rise to foreign exchange risk when the debt is remeasured into U.S. dollars at the end of each period. The remeasurement gains and losses are recorded in other